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Abstract 
Introduction and Aim: Pituitary adenomas are common neoplasms, with a reported prevalence of about one 
case in 1000 subjects. Patients with pituitary adenomas show significant morbidity due to pituitary hormone 
hypersecretion or deficiencies, mass effects and infiltration of the surrounding tissues. Although trans-
sphenoidal surgery and radiotherapy are largely used to treat patients with pituitary adenomas, the overall long-
term remission rate is not complete, beside side effects of surgery or brain irradiation. Therefore, medical 
treatments with pituitary-directed drugs are increasingly used in patients with secreting pituitary adenomas, 
especially when surgery fails or is not indicated, or awaiting for effects of radiotherapy. Somatostatin 
analogues (SSA) have been the mainstay of the medical treatment of GH-secreting adenomas, and nowadays 
are also used to treat ACTH-secreting pituitary adenomas, since these tumours express several types of 
somatostatin receptors (SSTR), with the prevalence of SSTR type 2 in the GH-secreting PA and of SSTR type 
5 in the ACTH-secreting. Regrettably, 50% of patients with GH- secreting and 60% with ACTH- secreting 
pituitary adenomas do not respond to medical treatment with pituitary-directed drugs, or present only a partial 
hormonal reduction. Receptor desensitization, internalization and intra-cellular trafficking of SSTR could 
explain at least partially the lack of response, hence more data and knowledge about these cellular processes 
are urgently needed. Moreover, pituitary adenomas are not always benignant: some aggressive cases (up to 15-
20% in all series) are characterized by rapid regrowth after first surgery, invasion of the surrounding structure, 
resistance to medical therapy, therefore the term Pituitary Neuroendocrine Tumor (PitNET) should be actually 
used. 
The aims of this PhD project are to describe the role of medical treatment in patients with PitNET, in order to 
study the efficacy of available compounds; applicate the combination of medical treatment in clinical practice; 
analyse the differential effects (if existing) of medical treatment compared to surgery (considered the best 
curative treatment). 
Materials and methods: Among our cohort of patients (120 with GH-, 134 with ACTH-, 171 with PRL-, 6 
with TSH- secreting PitNET, 150 with non-secreting PitNET), we retrospectively and prospectively analysed 
clinical, radiological and pathological features of patient. Considering the treatment of aggressive PitNET or 
patients with Cushing’s Syndrome, we focused our attention to everolimus, temozolomide (TMZ) and 
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metyrapone (MET) treatment. In some case, primary cell culture were used to study the effect of medical 
treatment.  
Results: Regarding medical treatment, we considered the use of everolimus, TMZ, cabergoline and MET.  
1. In a patient with tuberous sclerosis complex (TSC) and silent gonadotroph PitNET we tested the efficacy 
of everolimus, observing a reduction of cell viability after an in vitro treatment of PitNET’s derived 
primary cells. TSC analysis retrieved no disease-associated variants with the exception of the heterozygous 
intronic variant c.4006-71C>T found in TSC2: the computational tools predicted a gain of a new splice 
site with consequent intron retention, not confirmed by an in-vitro analysis of patient’s lymphocyte derived 
RNA.  
2. Regarding TMZ in aggressive PitNET, we conducted an Italian survey on 31 patients: 11 patients (35.5%) 
had reduction of the tumor during TMZ treatment, while 6 patients (19.4%) had progression of disease. 
Median follow-up after start of TMZ was 18 months. Seven patients presented disease progression. The 
2-yr recurrence-free survival was 62% (95% C.I., 34 -99%). Seven patients died of progressive disease. 
The 2-yr and 4-yr survival rates were 90% (95% C.I., 77-100%) and 56% (95% C.I., 26-85%). Moreover, 
we treated a patient with a combined cabergoline+TMZ treatment, achieving excellent results. 
3. Considering MET in patients with Cushing’s Syndrome, patients were treated with a median dose of 1000 
mg for 9 months. UFC and LNSC decreased quickly after the first month of treatment (-67% and -57% 
from baseline), with sustained UFC normalization up to 12 and 24 months (in 13 and 6 patients, 
respectively). UFC and LNSC normalized later (after 3-6 months) in patients with severe hypercortisolism 
(>5-fold baseline UFC). Regarding last visit, 70% and 37% of patients normalized UFC and LNSC, 
respectively. Body weight reduction (-4kg) was observed after UFC normalization. Severe side-effects 
were not reported, half female patients complained hirsutism, and blood pressure was not increased.  
4. In patients with acromegaly, a significant proportion of patients developed Central Adrenal Insufficiency 
(CA) over time: while primary or secondary medical treatment did not contribute to the risk of CAI, 
repeated surgery or radiotherapy affected pituitary-adrenal axis. CAI was diagnosed in 18% of patients 
(10/57) after surgery, and in 53% (9/17) after radiotherapy (p=0.01).  
Considering those aspects related to predict the effects of medical treatment with SSA in acromegaly, we 
studied the role of AIP-AHR and GIPR pathway. Considering AIP-AHR axis, involved in the detoxification 
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of endocrine disruptors and chemical pollutants, we observed that acromegaly is more biochemically severe 
and resistant to SSA treatment in patients living in highly polluted areas, especially if they also carry specific 
AHR and/or AIP gene variants. Moreover, we found a stimulatory effect of IGF-1 on GIP promoter support in 
GIPR-expressing somatotropinomas, suggesting a novel molecular pathway able to induce GH-secreting 
PitNET. 
Conclusions: In this complex scenario, understanding the physio-pathology of PitNET is the beginning of 
personalized treatment. In clinical practice, a multidisciplinary team for the management of patients is 
fundamental, to suggest the correct treatment plan, tailored to the patient. 
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Riassunto 
Introduzione e scopo: Gli adenomi ipofisari sono neoplasie frequenti, con una prevalenza di un caso ogni 1000 
soggetti. I pazienti con adenoma ipofisario possono presentare segni e sintomi in correlazione alla secrezione 
autonoma (o deficitaria) di ormoni ipofisari, oppure possono presentarsi come “effetto massa” dovuto alla 
lesione occupante spazio in loggia ipofisaria. Sebbene la chirurgia e la radioterapia siano state molto utilizzate 
in passato, il controllo a lungo termine non è completo, sia in termini di secrezione che di lesione adenomatosa, 
esponendo comunque il paziente agli effetti collaterali dell’intervento o dell’irradiazione. Pertanto, la terapia 
medica è sempre più utilizzata, non solo nelle recidive post-chirurgiche, ma anche quando ulteriori interventi 
sono inefficaci, o in attesa degli effetti della radioterapia. Gli analoghi della somatostatina (SSA) sono stati per 
anni la principale terapia degli adenoma GH-secernenti, e al giorno d’oggi vengono utilizzati anche in quelli 
ACTH-secernenti, dato il loro effetto differenziale sui recettori della somatostatina (SSTR), soprattutto il tipo 
2 nei GH-secernenti e il tipo 5 negli ACTH-secernenti. Purtroppo, fino al 50% dei pazienti non risponde in 
maniera soddisfacente alle terapie mediche, pertanto una maggior conoscenza della biologia cellulare 
ipofisaria è necessaria, per capire quale sia la strategia migliore per il paziente. Inoltre, in alcuni casi gli 
adenomi non sono sempre benigni (circa il 15-20% delle principali serie descritte in letteratura), 
caratterizzandosi per la resistenza alle terapie convenzionali, l’invasione dei tessuti locali o la rapida crescita. 
In tali casi, il termine Tumore Neuroendocrino Ipofisario (PitNET) viene recentemente proposto in letteratura. 
Lo scopo di questa tesi di dottorato è di studiare gli effetti delle terapie mediche in pazienti con PitNET; per 
sviluppare nuove strategie terapeutiche, per capire l’efficacia dei farmaci disponibili e per testare la loro 
combinazione. 
Materiali e metodi: I pazienti che sono seguiti presso l’ambulatorio ipofisi dell’Unità Operativa di 
Endocrinologia dell’Azienda Ospedaliero-Universitaria di Padova (120 con PitNET GH-secernenti, 134 
ACTH-secernenti, 171 PRL-secernenti, 6 TSH- secernenti e 150 PitNET non funzionanti) sono stati seguiti in 
uno studio retrospettivo e prospettico. I dati clinici, bioumorali, di terapia, radiologici e patologici sono stati 
raccolti e analizzati. Tra le varie terapie mediche, maggior risalto è stato dato all’everolimus e alla 
temozolomide (TMZ) nei PitNET aggressivi e al metirapone (MET) in pazienti con Sindrome di Cushing. In 
casi selezionati sono state allestite linee cellulari derivanti dall’adenoma del pazienti (primarie). 
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Risultati: in termini di terapia medica abbiamo analizzato 
1. In un paziente con sclerosi tuberosa e PitNET silente abbiamo testato l’efficacia dell’everolimus in colture 
primarie, osservando una generale riduzione della vitalità cellulare. Abbiamo poi riscontrato una nuova 
variante del gene TSC2, gli studi in silico predicono la ritenzione di un introne con perdita di un sito di 
splicing, che andrà confermato in ulteriori studi funzionali.  
2. Considerando la terapia con TMZ in PitNET aggressivi abbiamo raccolto i dati di 31 pazienti provenienti 
da uno studio multicentrico italiano. 11 casi hanno presentato una riduzione del PitNET, con una mediana 
di terapia di 18 mesi. Il 90% e il 60% dei pazienti erano liberi da malattia a 2 e 4 anni dalla terapia con 
TMZ. Abbiamo poi trattato un paziente con TMZ e cabergolina, ottenendo ottimi risultati. 
3. 31 pazienti con Sindrome di Cushing sono stati trattati per 9 mesi con 1000 mg di MET. I parametri 
ormonali (cortisoluria e cortisolo salivare notturno) si sono ridotti rapidamente già dopo un solo mese di 
terapia, normalizzando la secrezione di cortisolo fino a 12 e 24 mesi. I pazienti con ipercorticismo severo 
(>5 volte i valori normali al baseline) hanno raggiunto il controllo biochimico di malattia più lentamente, 
tuttavia il 70% dei pazienti normalizzava la cortisoluria all’ultima visita, con una riduzione media di peso 
di 4kg. In generale il MET era ben tollerato, senza importanti effetti collaterali.  
4. Nei pazienti con acromegalia, lo sviluppo di insufficienza surrenalica centrale (CAI) non è trascurabile nel 
follow-up. Mentre la terapia medica non aumenta il rischio di CAI, il 18% dei pazienti (10/57) svilippa 
iposurrenalismo dopo la chirurgia, mentre il 53% (9/17) lo sviluppa dopo la radioterapia. 
Analizzando in vitro gli aspetti che potrebbero predire la efficacia della terapia con SSA nei pazienti con 
acromegalia, abbiamo studiato i pathway molecolari di AIP-AHR e del GIPR. L’asse AIP-AHR, coinvolto 
nella detossificazione di varie molecole interferenti endocrine e inquinanti chimici, si trova maggiormente 
mutato in pazienti acromegalici con malattia più severa e con minor risposta agli SSA, soprattutto se vivono 
in zone molto inquinate. Abbiamo inoltre scoperto un ruolo promuovente del recettore dell’IGF-1 nel recettore 
del GIP, coinvolto nella tumorogenesi ipofisaria e quindi nuovo aspetto da studiare nei PitNET GH-secernenti. 
Conclusioni: Comprendere a fondo la fisiopatologia dei PitNET è l’inizio della personalizzazione della terapia 
medica, sempre più usata oggigiorno. Nella pratica clinica quotidiana, pertanto, un team multidisciplinare è 
fondamentale per proporre al paziente il corretto piano terapeutico, personalizzato secondo le proprie 
caratteristiche biologiche.  
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1. Background             
1.1 Pituitary Adenoma and Pituitary Neuroendocrine Tumor (PitNET) 
 
Molecular basis of pituitary adenomas 
Pituitary adenomas are increasingly recognised: their clinical prevalence is about 1/1000 inhabitants. Although 
considered benign, they induce significant morbidity due to pituitary hormone hypersecretion (prolactinomas, 
acromegaly, Cushing’s disease), mass effects (i.e. hypopituitarism, visual loss and other neurological 
symptoms) or infiltration of surrounding tissues1–5.  
Trans-nasal-sphenoidal surgery (TNS) is the first line treatment for the major part of patients with pituitary 
adenomas, however the overall long-term remission rate after TNS is reported about 60-70%, because surgical 
failures or recurrences are far from uncommon, occurring in up to 30-40% of patients, and increase with time6–
8
. Radiotherapy is a therapeutic option, but it has not always proved effective, and any benefit can take from 2 
to 10 years to become apparent, beside side effects of brain irradiation9,10. Moreover, some pituitary adenomas 
are characterized by a clinical “aggressive” pattern, in particular with an invasive local growth and/or 
resistance to conventional therapies (considering surgery, radiotherapy or medical treatment)11.  
Medical treatments with pituitary-directed drugs are increasingly used in patients with secreting pituitary 
adenomas, especially when surgery fails or is not indicated, or while awaiting for effects of radiotherapy7,12. 
Whether more or less aggressive, pituitary adenomas pose a serious therapeutic challenge for endocrinologists 
and neurosurgeons, and their treatment depends on functional phenotype and proliferation characteristics: 
current drugs act through endogenous receptors modulating the physiological pathways involved in the control 
of hormone secretion and growth.  
The characterization of cellular signalling mechanisms in patients with familial tumours (less than 5% of 
pituitary adenoma) represent an invaluable tool for a rational approach to sporadic neoplasms, which are more 
frequently diagnosed. Most inherited pituitary adenomas are due to germline mutations inactivating menin (in 
the MEN1 syndrome) or aryl hydrocarbon receptor (AHR)-interacting protein (AIP); these inherited pituitary 
adenomas are frequently more aggressive than their sporadic counterpart, and are diagnosed in 40% of cases 
in families with Familial Isolated Pituitary Adenoma (FIPA)13–15. Some patients with typical features of MEN-
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1 syndrome (parathyroid, pancreas and/or pituitary tumors) did not harbour mutations in menin, and are termed 
as MEN1-like. In about 10–20% of patients with MEN1-like features, a novel germline mutation in the 
CDKN1B gene, encoding for the cyclin-dependent kinase inhibitor p27KIP1, was associated with the 
development of pituitary adenomas16. Recently, X-linked acrogigantism (X-LAG) has been described as a new 
syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the gene 
GPR101, which is highly upregulated in pituitary tumours17.  
AIP-AHR is a crucial pathway in the somatotroph cell18, as reported in figure 1. AIP down-regulation at 
somatic level may occur during the progression of some GH-secreting pituitary adenomas, leading to 
acromegaly19. Other mutations at somatic levels have been recognized, in the past, that activate GNAS1 (Gsp-
a, subunit of the heterotrimeric stimulatory G protein that gives to somatotroph cells a growth advantage)20. 
Recently, somatic mutations in USP8 (a deubiquitinase gene, involved in the reversible post-translational 
protein modification regulating the fate and function of various proteins in eukaryotic cells) have been also 
recognized in ACTH-secreting pituitary adenomas (characterizing Cushing’s Disease, CD)21,22.  
 
 
Figure 1: AIP-AHR pathway. In case pf AIP mutation, Phosphodiesterase 2A (PDEA2) and heat shock protein 90 (HSP 
90) are released in the cytoplasm, enabling AHR and AHR Nuclear Translocator (ARNT) to promote cell growth. 
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Inactivating mutations of the AIP gene, encoding for a co-chaperone cytoplasmic protein involved in the 
regulation of AHR activity and in many other intracellular interactions, have been found in 40% of patients 
with isolated familial somatotropinomas14,15,23. Moreover, mutations in AIP gene are involved in the resistance 
to Somatostatin Analogs (SSA) in patients with acromegaly24,25. Recently, a novel close relationship with 
environmental factors (endocrine disruptors and pollution) has been proposed. Increased prevalence of 
acromegaly was demonstrated in a district of the province of Messina (Sicily, Italy), identified as high-risk for 
health (HR) area by the Italian government on the basis of high atmospheric concentrations of pollutants and 
endocrine disruptors, as non-methane hydrocarbons and volatile organic compounds. The prevalence of 
acromegaly in this polluted area reached 210-300 cases per million inhabitants; the relative risk of developing 
acromegaly was 8-10 fold higher than a reference area with low industrial density (and therefore a reduced 
pollution and air contamination of endocrine disruptors)26. Preliminary in vitro studies showed that long-term 
incubation with some endocrine disruptors, as phenol and bis-(2-ethylhexyl)-phthalate, increases energy 
content and proliferation of normal pituitary cells, in rats as well as in humans27. In addition, the long-term 
benzene exposition increased GH synthesis in GH3 cells (a murine model of acromegaly), and this effect was 
associated with decreased AIP and increased AHR expression, with a potential impairment of the sensitivity 
to SSA28. The AHR pathway has a key role in cellular detoxification mechanisms and several studies suggest 
that it is implicated in tumorigenesis, not only in the pituitary29.  
Another interesting feature that could be used to characterize GH-secreting pituitary adenoma, and that could 
be used to personalize the therapeutic approach, is to study the response of GH to a Oral Glucose Tolerance 
Test (OGTT). In patients with active disease, a standard 75-gr OGTT fails to suppress serum GH levels <1 
μg/L, however in approximately 30% of cases GH levels increase paradoxically30. With the aim of clarifying 
the pathogenesis of pituitary adenoma in acromegaly, we recently focused our attention to the glucose-
dependent insulinotropic polypeptide (GIP) receptor (GIPR), a member of the G-protein-coupled receptors 
superfamily (GPCR)31. Once activated by GIP, which is secreted by the K cells of the duodenum in response 
to mixed meals, GIPR transduces extracellular stimuli into intracellular responses by activating the cAMP 
pathway32,33. In normal basal conditions, the glucose-dependent secretion of insulin in pancreatic β cells after 
GIP stimulation exemplifies this mechanism34. When inappropriately expressed in the adrenal gland, the GIPR 
may instead result in the development of adrenal tumors, disrupting cAMP homeostasis by altering the cascade 
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normally triggered by ACTH35, leading to the so-called food-dependent Cushing’s syndrome36. In 2011 we 
reported that nearly 30% of GH-secreting PitNET expressed GIPR at significantly higher levels than normal 
pituitary glands37. Correlation of molecular findings with clinical data revealed that, in most cases, GIPR 
overexpression was associated with a paradoxical increase in GH after OGTT37,38. Similar to what is observed 
in food-dependent adrenal CS, in GIPR-overexpressing GH-secreting PitNET, GH is inducible by meal39. 
These acromegalic patients show abnormally high fasting and postprandial plasma GIP levels40; this may be 
the consequence of a direct effect of GH, IGF-1 or both on GIP secretion. Based on these premises, the link 
between the GIP/GIPR axis and GH induction in GH-secreting PitNET primary cultures has never been 
studied. 
 
Aggressive pituitary adenomas 
Besides molecular characterization, pituitary adenomas are usually considered benign tumors1, although some 
of them can exhibit an aggressive behavior. In such cases, their treatment plan is a challenge, and repeated 
surgery or additional medical treatment or radiotherapy is needed41. The crucial issue is to early identify this 
patients42, which may coincide only partially with the atypical adenomas described in the 2004 WHO 
histological classification (characterized by MIB-1 >3%, p53 immunoreactivity, high mitotic index11,43), 
accounting only for 3-15% of cases in surgical reported series44,45. In clinical practice, a close relationship 
among atypical adenomas and aggressive behavior is not always evident, since typical adenomas can show an 
aggressive behavior as well43,46. Beside “atypical adenoma” definition, some patients with clinically aggressive 
pituitary adenomas are diagnosed among those with large or invasive masses, or considering those adenoma 
resistant to conventional treatments (neurosurgery, drug or radiotherapy), therefore presenting with earlier and 
more frequent recurrences, or even those defined as silent adenoma1,44–46. In Table 1 are summarized the most 
relevant features that characterize aggressive pituitary adenomas. 
In clinical practice, “Aggressive” definition is often used by way of “invasive” or “atypical”, though they are 
not synonymous. Invasiveness is defined by radiological or surgical findings, and, on the other hand, 
aggressiveness is defined by clinical behavior, while atypical adenoma are defined on the basis of pathological 
report11,43,47. 
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Table 1: definition of aggressive PitNET routinely used in clinical practice and during the multidisciplinary meeting. CSI: 
cavernous sinus invasion (Publication IV. Ceccato F, Acta Neurochir, 2017) 
 
feature description references 
tumor growth tumor growth (>20% in one diameter) in pituitary MRI in the last year 
despite therapy (if any) 
 
invasive adenoma MRI, computed tomography or surgical evidence of at least one: 
- CSI: encasement of internal carotid artery ≥45% of the vessel 
circumference or when there was an involvement of at least three 
out of four cavernous sinus compartments (medial, superior, 
inferior, lateral) by the adenoma 
- sellar floor involvement 
- third ventricle involvement 
48,49
 
giant adenoma > 4 cm in adults 41,50,51 
atypical adenoma histological report of  MIB-1 >3%, positive p53 immunoreactivity, high 
mitotic index 
11
 
resistance to pituitary-
directed pharmacological 
treatment 
Uncontrolled hormone secretion despite two consecutive years of 
conventional pituitary-directed pharmacological treatment 
- PRL-secreting adenoma: cabergoline >2 mg/week 
- GH-secreting adenoma: >120 mg/month lanreotide autogel or > 30 
mg/month octreotide LAR 
3,8
 
silent adenoma non-functioning PitNET with positive immunohistochemistry for 
ACTH, GH, PRL, TSH, LH or FSH.  
44,45
 
  
 
 
The fourth edition of the World Health Organization classification of endocrine tumors has been published in 
late 2016. There are 3 main changes to the previous (2004) classification:  
- the term "atypical adenoma" was completely eliminated due to the lack of definitive evidence in terms of 
a poor prognosis;  
- the introduction of more precise cell lineage-based classification of pituitary adenoma that is defined 
based on lineage-specific transcription factors and hormones produced;  
- the new term of pituitary neuroendocrine tumors (PitNET) with the elimination of the term “atypical 
adenoma52,53.  
This recent classification is closer to the aggressiveness of the pituitary adenoma, and introduce the concept 
that a single clinical disease (i.e. acromegaly) could represent the final clinical manifestation of more than one 
different neuro-endocrine tumor (a GH-secreting PitNET). One year later, some authors proposed that a new 
classification of PitNETs into five grades based on invasion on MRI and immunocytochemical profile (as 
reported in table 2) is of prognostic value to predict postoperative tumor behavior and identifies those patients 
who have a high risk of early recurrence or progression47.  
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Table 2: 5 grades of PitNET47  
 
Grade Description 
1a Non-invasive 
1b Non-invasive but proliferative 
2a Invasive 
2b Invasive and proliferative 
3 Metastatic 
 
 
To conclude, an aggressive PitNET is a tumor with a low likelihood of being cured, especially with surgery 
alone. In such scenario, medical treatment may play a crucial role, to reduce or at least to stabilize the 
progression of PitNET. The development of new drugs relies on a better knowledge of the heterogeneous 
molecular abnormalities driving pituitary tumorigenesis, possibly focusing on intracellular pathways to be 
targeted with a low toxicity. Moreover, it is fundamental to discover new clinical or molecular findings to 
predict the aggressive behavior of PA, in order to identify those patients that require a close follow-up. Rather 
than new molecules, which development requires several years “from bench to bed”, there are increasing 
evidence that combination of available drug could be an effective strategy. 
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1.2 Medical Treatment in PitNET 
 
Medical treatment in Cushing’s Syndrome (CS) 
For ACTH-secreting PitNET, called Cushing’s Disease (CD), the treatment goals (with surgery, radiotherapy 
or medical therapy) are to normalize cortisol levels, reverse the clinical symptoms, and remove the secreting 
neoplasm6.  Adrenal steroidogenesis inhibitors have been the mainstay of medical treatment for CD: the most 
used are ketoconazole and metyrapone. The available glucocorticoid receptor antagonist is mifepristone, is 
approved in the USA to control hyperglycemia secondary to hypercortisolism. There has recently been a lot of 
interest in using agents directly targeting the pituitary corticotroph cells to reduce ACTH secretion and, if 
possible, control the volume of pituitary adenomas. This is because corticotroph cells contain dopamine 
receptors (targets of bromocriptine and cabergoline), retinoic acid receptors, peroxisome proliferator-activated 
receptor gamma, or SSR, the target of the first drug developed and approved for Cushing’s Disease 
(pasireotide)54,55. 
Available medical treatments for Cushing’s Syndrome (CS) are: 
• Ketoconazole (KET), used off-label to reduce hypercortisolism because of its effect to reduce the activity 
of cytochrome P450 adrenal steroidogenic enzymes, including 11β-, 17α- and 18-hydroxylase56,57. 
Lowering cortisol in CD patients may trigger an ACTH response from the pituitary adenoma, with the risk 
of escape from treatment efficacy and a consequent secondary failure of medication. KET can be used as 
a temporary adjunct before a more definitive treatment, or after unsuccessful neurosurgery. One of the 
problems with ketoconazole is the paucity of published data on its use. Most studies concerned small 
samples, and no prospective clinical trials have been conducted so far56,57. A reduction of cortisol levels 
was usually achieved with 600-800 mg/day, obtaining overall response rates of 53-88% in CS, and 45% 
in CD. In 2014 a multicenter retrospective study reported UFC normalization in 49% of patients, and in 
another 23% the UFC levels were reduced by at least 50%, using a median final dose of 800 mg/daily; on 
the other side a quarter of patients on long-term follow-up were treated inadequately. In 20% of cases the 
drug was administered prior to surgery, obtaining UFC normalization in 49% of cases. Hypertension, 
hypokalemia and diabetes improved in 40-50% of patients, but 20% of them abandoned the treatment due 
to poor tolerance57.  
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• Metyrapone (MET) inhibits the conversion of 11-deoxycortisol into cortisol by 11β-hydroxylase 
(CYP11B1), the final step in cortisol steroidogenesis, namely with a nadir in cortisol levels within 2 hours 
of its administration. Despite inducing a rise in ACTH, it is an effective long-term treatment when used 3-
4 times a day58–60. Verhelst et al. reported that MET induced a remission of hypercortisolism in 20 out of 
24 pituitary-irradiated patients with CD, and in 13 out of 16 patients with cortisol-secreting adrenal 
adenoma or carcinoma. Valassi et al. demonstrated UFC normalization in 57% of 23 patients treated with 
MET alone, and clinical control of the disease was achieved in 46% of them. In other studies, MET was 
administered to CD patients before therapy: a drop in mean serum cortisol was observed as soon as 48-
72h later, and after 2 weeks the disease was controlled in 75% of patients. ACTH levels rose over 4 to 6 
weeks, using a median dose of 2000 mg/d in weeks 1-3, which was raised to 2250 mg/d (range 500-6000) 
by week 6. In 2015 a large retrospective study in 13 University-Hospitals in UK reported that MET 
treatment is effective for short- and long-term control of hypercortisolemia in about 200 patients 
(considering both benign and malignant form of CS), achieving UFC normalization in 43% of cases after 
median 8 months (from 3 months to 12 years)60. The optimal MET dosage has yet to be defined because 
it has never been the object of a rigorous clinical trial.  
• Cabergoline (CAB) is an agonist of dopamine receptor type 2 (D2), which is expressed in about 80% of 
corticotroph tumors, and the in vitro and in vivo demonstration that dopamine agonists can reduce ACTH 
secretion, led to the introduction of this class of drugs in the treatment of CD12,61,62. After 3 months of 
CAB, UFC levels had dropped by more than 25% compared to the baseline in 75% of the patients, even 
though a cortisol drop of 25% from baseline is a lower criteria than that of 50% used as a response cut-off 
in other clinical trials. 35% of patients were full responders and enjoyed a prolonged remission on median 
doses of 3.5 mg/week, without reporting no significant adverse events12,61,62. A recent meta-analysis shows 
that CAB monotherapy is a reasonable alternative for subjects with persistent or recurrent CD after surgery, 
achieving controls of hypercortisolism in 39% of patients (124 cases in 6 observational studies), especially 
after long-term or high-dose treatment63. 
• Retinoic acid (RA) is able to reduced pro-opiomelanocortin synthesis and ACTH secretion in a murine 
tumoral corticotroph model, exerting also an antiproliferative action on adenoma cells64,65. In a small 
prospective clinical trial, UFC levels dropped by at least 50% or normalized in 5 of 7 patients after 6 
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months of orally-administered RA (up to 80 mg daily). Interestingly, after an initial decline in ACTH 
levels during the first month of treatment, ACTH levels returned to the pretreatment range. In all patients, 
RA was generally well tolerated, and only mild conjunctival irritation, nausea, headache and arthralgia 
were observed64. In 2016 a prospective study in 16 patients with CS confirmed a mean UFC reduction of 
52%, achieving its normalization in 25% of cases (especially in those patients with mild 
hypercortisolism)66. An in vitro study examined the effect of administering RA and bromocriptine, given 
the well-known permissive role of RA on the D2. In the pituitary corticotroph cell line AtT20, 
administering RA induced D2 and increased cell sensitivity to bromocriptine; and in corticotropinoma-
derived primary cultures, the combined administration of RA and bromocriptine lowered the steady-state 
level of proopiomelanocortin more efficiently than either of the drugs alone65. 
• Pasireotide (PAS) is a novel SSA approved by the EMA and FDA for treating adult patients with CD when 
surgery has failed, hypercortisolism has recurred, or surgery is not an option. Naïve somatostatin binds 
with a high affinity to all five subtypes of SSTR expressed on the target tissues: in corticotroph adenomas 
the membrane density of SSTR-2 is lowered by hypercortisolism, while that of SSTR-5 is unaffected, and 
this latter receptor is the target of pasireotide67,68. In the first clinical trial, two weeks of treatment with 
PAS 600 µg bid sc. reduced UFC in 76% of cases, with a mean 45% reduction from patients’ baseline 
levels67. In a III-phase trial, 162 patients with CD were randomized to receive PAS 600 or 900 μg bid, 
stepping up the dosage after 3 and 6 months, up to the maximum of 1200 μg bid. Patients’ UFC levels 
dropped quickly, with a median reduction of approximately 50% after 2 months of therapy, and remained 
stable in the first year, by the end of which 13% of patients in the 600 μg and 25% of those in the 900 μg 
group had normal UFC levels68.  PAS has proved effective not only in lowering UFC, but also in improving 
clinical signs and symptoms (blood pressure, body weight, lipid profile and anxiety disorders). Recently, 
a long-acting formulation of PAS (one-monthly injection, 10 30 or 40 mg) has been described in a phase 
III international prospective trial: it normalised UFC concentration in about 40% of patients with CD after 
7 months, it had a similar safety profile to that of twice-daily subcutaneous PAS and therefore provides a 
convenient monthly administration schedule69. PAS induce a worsening of glucose control (not only in 
diabetic patients) in up to 75% of patients, affecting the incretin system70. 
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Combinations of drugs targeting different levels of the pituitary-adrenal axis may prove more effective while 
containing side effects and cost by reducing the average dose of each compound, but published reports 
addressing this aspect of CD treatment have only considered small series. The first study concerned 12 patients 
with persistent disease treated with CAB at an initial dose of 1 mg, raised to a maximum of 3 mg/week or until 
UFC levels returned to normal. After 6 months, 3 patients had normalized UFC levels with a mean dose of 2.5 
mg. KET then was associated to the treatment with CAB in the other 9 patients, starting with a dose of 200 mg 
and increasing to a maximum of 400 mg/day, on the basis of the cortisol reduction obtained. Overall, 9 of the 
12 patients (75%) achieved a normal UFC. Interestingly, the responders had lower baseline UFC levels than 
the non-responders71. Barbot et al. examined 14 patients with CD. The sample was divided into 2 groups: the 
first treated with CAB (n=6, maximum dose 3 mg/week), adding KET after 6 months; the second (n=8) with 
the same combination of drugs in reverse. Overall, UFC levels were normalized in 79% of cases, with no 
differences between the two treatment schedules. It is noteworthy that, despite normal UFC levels, 10/14 
patients still had high late night salivary cortisol (LNSC) levels, presumably reflecting a subtle 
hypercortisolism that may be detrimental72. In another 80 days trial, 17 patients with CD were treated first with 
PAS 100 μg sc. bid, then with 250 μg sc. tid daily as of day 15 in patients with persistently high UFC levels. 
At day 28, CAB was added at a dose of 0.5 mg every other day, stepping up the dose to 1.5 mg every other 
day after 10 days if UFC levels remained abnormal. Then KET 600 mg daily was added at day 60 if UFC 
levels were still elevated. The disease was controlled with the first two drugs in 47% of patients, and in 88% 
after adding low-dose ketoconazole. Despite the small size of this series, the study clearly points to unexplored 
potential advantages of combination therapies73. Every physician must bear in mind that both pasireotide and 
ketoconazole can prolong the Q-T interval, hence in association they should be used with caution in patients 
at risk of arrhythmia. 
Considering cortisol-related comorbidities, currently few papers studied body composition changes in adult 
patients with CS after achieving remission. Three prospective works with different techniques (computed 
tomography, bioelectrical impedance analyses or magnetic resonance), reported a decrease of total body and 
fat mass in 7, 6 and 14 patients after remission74–76. Furthermore, three cross-sectional studies considering 37, 
50 and 58 subjects evaluated with dual-energy X-ray absorptiometry (DXA) reported that fat mass was higher 
after stable remission of CS than in healthy controls77–79. Therefore, it is not yet clear whether body 
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composition is normalized after remission of hypercortisolism. Moreover, there are no published data 
regarding the effects of different treatments on body composition, as surgery (first-line treatment for CS, if 
possible) or pharmacological therapy (increasingly used, especially after surgical failure or waiting for 
radiotherapy’s effect).  
 
Medical treatment in GH-secreting or PRL-secreting PitNET 
One of the first pharmacological options in GH-secreting PitNET are SSA, acting mainly through the 
somatostatin receptors type 2 (SSTR2) and type 5 (SSTR5) and to lesser extent dopamine-agonists, activating 
dopamine receptor type 2 (DRD2).  
Treatment goals in acromegaly include normalisation of GH and IGF1 levels, tumour removal or at least 
significant reduction or stabilization of tumour size, preservation of normal pituitary function, reduction of 
comorbidities and improvement of quality of life3,7,30,80. 
Surgery is generally the first-line therapy for acromegaly, and it is the only therapy that may lead to lasting 
remission, especially in microadenomas (up to 80-90%). Radiotherapy in the form of conventional or 
stereotactic fractionated treatment is required for the treatment of a few patients with acromegaly81. 
By contrast, medical treatment is quite often indicated as adjuvant therapy, and SSA is usually the first drug 
of choice7.  
• SSA: Two SSAs are available and used worldwide: octreotide long-acting repeatable (LAR) and lanreotide 
Autogel: no blinded or randomised study that has compared octreotide LAR with lanreotide Autogel in de 
novo acromegalic patients has been published81. Some authors suggest that a switch between somatostatin 
analogues may be beneficial in individual patients, if i) the patient is a non-responder or ii) the patient 
develops subcutaneous nodules at the injection site and/or adverse gastrointestinal effects82. Presurgical 
lanreotide treatment have generated promising results, especially in larger adenomas83. SSAs are 
established treatments for patients with acromegaly after unsuccessful pituitary surgery; meanwhile, 
primary therapy with these agents is recommended principally for a subgroup of patients with larger 
tumors when a surgical cure is unlikely, and additionally if surgery is refused or contraindicated7. In 2013, 
an international collaborative study considered lanreotide 120mg monthly as a primary treatment 
(PRIMARYS study) in 90 patients: after 12 months of treatment they observed a significant reduction in 
Ceccato, Personalized medical treatment for pituitary adenoma, PhD thesis, pag 22 
tumor volume (at least 20% as per protocol) was observed in 63% of patients83. To date, the normalization 
rates of GH or IGF-1 after first-generation SSAs (lanreotide or octreotide) is up to 55%84. Recently, PAS 
has been proposed and compared to octreotide in a prospective trial, achieving a higher rate of acromegaly 
control 85,86.  Future studies and extensive clinical experience (especially regarding PAS-induced diabetes) 
will determine the impact of this new SSA. 
• Pegvisomant (PEG) is a 191-amino acid compound, initially developed as a new GH analogue (as a matter 
of fact most currently available assays cross-react with it), but it is an effective GH antagonist.  PEG 
decreases IGF1 levels effectively in most patients, achieving IGF1 normalization in up to 90% of patients 
with 10–40 mg/day for 12–18 months87,88. PEG does not reduce tumour size as SSAs, and a minor part of 
patients (2–3%) exhibited a significant increase in tumour size, therefore periodic MR is suggested81. 
• CAB: Dopamine agonists were available for the medical treatment of acromegaly until the 80s. CAB is 
the most used, with a good safety profile, especially in mild cases. The use of CAB as a monotherapy after 
unsuccessful surgery has only been evaluated in small series: in a meta-analysis, the efficacy of CAB as a 
monotherapy (10 observational studies for 11 months, 160 patients, no randomized or placebo-controlled) 
to normalize IGF-I was 34 %. Normalization of both GH and IGF-I levels was observed for 39 % of the 
patients if CAB is combined to SSAs89,90. However, little evidence is available in the literature regarding 
its use in acromegaly. 
New data obtained on the processes involved in receptor desensitization, internalization, and intra-cellular 
trafficking could explain the lack of response to drugs, such as: 
 Low (or absent) expression of SSTR receptor in the cell membrane 
 High expression of truncated SSTR variants 
 Cytoskeleton alterations, as cadherin or arrestin mutations, that interfere with intra-cellular trafficking 
of the SSTR 
 Low or mutated AIP expression 
 Low (or absent) expression of dopamine receptor DRD2 in the cell membrane 
 Mutations in cyclin-dependent kinase inhibitors, atypical tumour suppressors genes playing a key role 
in cell cycle regulation, cell proliferation, and differentiation (i.e. p27)30,91. 
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Prolactin-secreting pituitary adenomas are generally characterized by an excellent response to dopamine-
agonists (DAs, especially cabergoline), considering both prolactin secretion and tumor-size reduction8. 
Overall, up to 90-95% of patients with microprolactinomas and 70-80% of those with macroprolactinomas 
have normalized prolactin levels, reduced tumor sizes, and restoration of gonadal function with cabergoline92. 
Therefore, DA therapy is recommended as first-line treatment, also in patients with mass-effect symptoms8. 
Despite size and secretion, the term “insufficient response to cabergoline” may be better than “resistance to 
cabergoline”, because dopamine-agonist treatment was effective to reduce prolactin levels. In such cases, 
indication to cytoreductive surgery should be carefully considered and balanced, because complete surgical 
removal of a giant prolactin-secreting PitNET is challenging and tumour persistence after surgery occurs 
frequently93.  
 
Medical treatment in aggressive PitNET 
In aggressive PitNET, whether definition used, other options needs to be considered after the failure of surgery, 
radiotherapy and conventional medical treatment.  
Temozolomide (TMZ) is an alkylating agent that undergoes rapid chemical conversion in the systemic 
circulation at physiological pH to the active compound [5-(3-methyltriazeno) imidazole-4-carboxamide]. The 
cytotoxic effect of this active metabolite is accomplished through the methylation of guanine at the O6 position 
in DNA, causing formation of DNA adducts and subsequent autophagy, senescence, and apoptosis of 
neoplastic cells94. TMZ is administered orally, has 100 % bioavailability, readily crosses the blood–brain 
barrier, is not cell-cycle specific, which is advantageous when treating relatively slow-growing tumors95. The 
first case reports on the use of TMZ in pituitary adenomas or carcinomas were published in 200696,97, then 
several authors reported its efficacy11,98, and now TMZ has a place in the therapeutic algorithm recently 
proposed by the European Society of Endocrinology to manage aggressive PitNET5,99. Response to TMZ was 
initially reported to depend on the adenoma’s expression of 6 methylguanine DNA methyltransferase 
(MGMT), a DNA repair enzyme that has the potential to interfere with the action of TMZ98. TMZ treatment is 
not effective in all aggressive PitNET, so other therapeutic options may be useful: in such scenario, in 2014 
we described the association of PAS and TMZ in a series of patients with aggressive ACTH-secreting PitNET, 
achieving a significant improvement in both endocrine secretion and shrinkage of the adenoma100. 
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Medical treatment in non-secreting PitNET 
Translational medicine is one of the modern cornerstones in “bench-to-bed” research. In such scenario, some 
genetic inherited alterations could represent a “simple” model of disease, useful to understand the physio-
pathology of cellular transformation. As an example, Tuberous Sclerosis Complex (TSC) is an autosomal 
dominant multisystem hereditary cutaneous condition, characterized by multiple hamartomas that can be 
associated to endocrine system alterations101,102. TSC is mostly caused by mutations of two tumor suppressor 
genes TSC1 and TSC2, encoding for hamartin and tuberin, respectively. In normal cells hamartin and tuberin 
form a molecular complex involved in intracellular signaling pathways controlling cell growth and 
proliferation, including the mammalian target of rapamycin (mTOR) cascade. Therapeutic approach related to 
mTOR signaling, such as everolimus, may be used in some patients with pituitary adenoma101,102. In nearly 
10% of cases mutations are mosaic or intronic and a comprehensive genotype-phenotype correlation is still 
debatable. About two thirds of TSC cases are sporadic reflecting a high spontaneous mutation rate in these 
genes103. Some reports addressing PitNET in TSC patients suggest the possible involvement of pituitary gland 
alterations in the pathological process of TSC104. The development of pituitary tumors by nearly half of adult 
Eker rats (with spontaneous germline mutation of TSC2) further supports this possible association105. Up to 
now, however, no molecular evaluation of PitNET in patients with TSC has been performed to establish the 
weight of this link and wheter PitNET should be considered a clinical manifestation of TSC is far from being 
clearly understood. 
In conclusion, there is still a considerable number of patients with PitNET without a personalized and effective 
medical treatment after surgical failure or recurrence: in these patients, a clinical and molecular 
characterization may guide medical treatment, in order to personalize their therapeutic plan. 
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2. Aim   
           
The aim of this PhD project is to study the effects of medical treatment in patients with PitNET, in order to: 
- Develop new medical treatment or strategies 
- Study the efficacy of available medical treatment  
- Applicate the combination of medical treatment in clinical practice 
- Analyse the differential effects (if existing) of medical treatment compared to surgery (considered the best 
curative treatment) 
 
Different methodological approaches have been adopted during the 3 years of project, in order to address 
correctly the aims: 
- A case-report study in the in-vitro everolimus-treated patient 
- An observational planned study with decided doses of medical treatment to establish the effect of MET in 
patients with CS 
- A cross-sectional study to analyse the effect of different approaches (medical treatment, surgery or 
radiotherapy) regarding the clinical picture of patients with acromegaly or CS. 
- Literature review and retrospective analyses of our cohort of patients in case of aggressive PitNET 
- In-vitro studies regarding cell-lines or primary-cell culture 
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3. Materials and methods         
3.1 case identification and clinical analyses  
 
Among our cohort of patients that are followed in the Pituitary Office of the Endocrine Unit of Padova (120 
with GH-, 134 with ACTH-, 171 with PRL-, 6 with TSH- secreting PitNET, 150 with non-secreting PitNET), 
we retrospectively and prospectively analyzed clinical, radiological and pathological features. 
 
We collected cross-sectional data from 97 patients with acromegaly and normal Hypothalamic-Pituitary-
Adrenal (HPA) axis function at diagnosis of acromegaly, 38 males and 59 females, with a mean age of 60±13 
years (range 31-92). Their mean age at the time of their diagnosis was 46±13 years (range 24-78) and they had 
a mean follow-up (as at December 2017) of 14±10 years. We considered only those patients with a complete 
follow-up, discarding those cases with insufficient data or follow-up (at least 2 years of observation after 
diagnosis). Acromegaly was managed according to current international criteria3,80. The diagnosis was based 
on clinical characteristics; inadequate GH suppression (<1 μg/L) after an oral glucose tolerance test (OGTT); 
and high IGF-1 levels for gender and age. Disease activity was judged on the last available visit. We considered 
the disease as “active” when randomly-measured serum GH was ≥1 µg/L or IGF-1 levels were below the upper 
limit of normality in patients with clinical symptoms of active acromegaly, and the GH nadir after OGTT was 
≥1 μg/L. Acromegaly was judged to be “controlled” when randomly-measured GH levels were <1 µg/L and 
IGF-1 values were within normal range. Normal IGF1 levels were used to consider remission in patients treated 
with pegvisomant. Adenoma was classified by maximal diameter as micro-adenoma (<10 mm) or macro-
adenoma (≥10 mm), and cavernous sinus invasion (CSI) was assumed from MRI evidence, diagnosed while 
during transsphenoidal surgery. SSA (octreotide LAR or lanreotide autogel), CAB or pegvisomant (that is only 
allowed in Italy for patients who have undergone surgery) were used as medical treatment. We assessed in all 
97 patients basal morning (07.00 – 09.00 a.m.) serum cortisol at diagnosis, and then every 12-18 months during 
the follow-up, or whenever cortisol deficiency was clinically suspected (serum cortisol was checked back the 
next morning if too high or too low, considering pulsatile secretion). Adrenal insufficiency was diagnosed if 
F0 <138 nmol/l, or if cortisol response to low-dose short synacthen test (LDSST) was inadequate106,107.  
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To study the effect of MET in patients with CS, an ad-hoc designed observational trial (depicted in figure 2), 
has been created and studied. 31 consecutive patients with confirmed CS were enrolled and treated with MET 
for at least 4 consecutive weeks. 
CS was diagnosed with at least two positive first line screening tests among UFC, LNSC and 1-mg 
dexamethasone suppression test (DST). We considered CD in those patients with positive ACTH immuno-
staining of the pituitary adenoma or ACTH pituitary/peripheral gradient >3 after CRH stimulation in petrosal 
sinus sampling or at least two of the following criteria: a) at least 80% decrease of serum cortisol after 8 mg 
DST; b) ≥50% rise in ACTH or ≥20% rise in cortisol levels after CRH stimulation test; c) MRI confirmation 
of a pituitary adenoma ≥6mm; d) ≥6 months remission after pituitary surgery. The other ACTH-dependent CS 
patients were ectopic-CS. We considered adrenal CS in those patients with ACTH levels <10 ng/L and positive 
finding of an adrenal lesion. 
All patients presented with hypercortisolism at baseline, defined as at least one among increased UFC levels 
or impaired cortisol rhythm with increased LNSC. The effectiveness of medical treatment was stratified 
considering baseline cortisol levels (either salivary or urinary) compared with upper limit of normality (ULN) 
in Padova’s University-Hospital, as depicted in table 3. 
 
 
 
Table 3: stratification of hypercortisolism severity according to cortisol levels at baseline visit.  
 
 ULN UFC nmol/24h LNSC nmol/L 
Normal <1 <168 <2.6 
Mild hypercortisolism  1-1.5 169-252 2.7-3.9 
Moderate hypercortisolism  1.5-2.5 253-420 4-6.5 
Severe hypercortisolism  2.5-5 421-840 6.6-13 
Very severe hypercortisolism >5 >841 >13.1 
 
 
LNSC and UFC (two collections at each visit) were assessed after one month, 3 months (the core phase of the 
protocol), 6 months, 1 year and 2 years (for those subjects in the extension phase). Inclusion and Exclusion 
Criteria are depicted in table 4. 
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Figure 2: study design scheme 
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Table 4: inclusion and exclusion criteria for patients with CS.  
 
 
Inclusion Criteria Exclusion Criteria 
Age >18 years at the baseline visit Pregnancy, lactation 
Biochemical evidence of CS Previously pituitary radiotherapy. 
In patients treated with MET before surgery 
with normal mUFC (mean of 3 UFC 
collections) or mild/moderate increase of 
mUFC at baseline, pseudo-Cushing’s 
(functional hypercortisolism) exclusion was 
based upon increased mLNSC (mean of 2 
LNSC collections) and unsuppressed serum 
cortisol after 1-mg DST 
Patients who have a history of congestive heart failure 
(NYHA Class III or IV), unstable angina, sustained 
ventricular tachycardia, clinically significant 
bradycardia, advanced heart block, acute MI less than 
one year prior to study entry, or clinically significant 
impairment in cardiovascular function  
Biochemical hypercortisolism at baseline 
before MET treatment (at least one among 
increased mUFC or mLNSC levels). 
CS surgery: trans-nasal approach for CD, abdominal 
surgery for ACS or selected surgery (thoracic or 
abdominal) for EAS during MET treatment 
At least 30 days post-surgery in those patients 
with a history of prior surgery. 
Malignant disease. 
Washout to prior current drug therapy, if the 
treatment was not tolerated or not able to 
normalize mUFC. The following washout 
periods were completed before baseline visit: 
ketoconazole: 2 weeks; pasireotide s.c.: 2 
weeks; cabergoline: 4 weeks; mitotane: 6 
months. 
Patients with risk factors for torsade de pointes, i.e. 
patients with a baseline corrected QT interval >470 ms, 
hypokalemia, hypomagnesemia, family history of long 
QT syndrome, or concomitant medications known to 
prolong QT interval that could not be discontinued.  
 Combination of another medical treatment to control 
hypercortisolism 
Patients who have had any previous MET treatment 
Radiotherapy while on MET treatment 
Impaired liver (history of liver disease such as cirrhosis, 
chronic active hepatitis B and C, ALT or AST >2 ULN, 
baseline total bilirubin >1.5 ULN) or renal function 
(serum creatinine >2.0 X ULN). 
MET discontinuation before 4 weeks of treatment 
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Regarding aggressive PitNET, we considered an aggressive pituitary adenoma when at least one of the items 
summarized in table 1 was met: tumor growth, invasive adenoma, giant adenoma, atypical adenoma, resistance 
to pituitary-directed pharmacological treatment, silent adenoma. All patients referred to Padova University-
Hospital (mean follow up 6±5 years), either in Endocrine or Neuro-surgery Unit. 
We considered response to surgery in case of complete removal of the adenoma, evaluated with hormonal 
secretion and pituitary magnetic resonance imaging (MRI) 3-6 months after procedure. Response to 
radiotherapy was defined in case of radiological disappearance of adenoma at MRI and normalization of 
hormonal secretion (if present) at least 3 years after irradiation. Control of hormonal secretion and tumor 
growth were considered to define the response to standard dose of medical therapy (at least 2 consecutive 
years). 
In aggressive PitNET the stratification of response could be cumbersome, therefore we decided to grade it 
considering a “pituitary-adapted” RECIST criteria. Patients who had a complete (disappearance of the tumor), 
or a partial response (decrease in tumor volume >50 %), or stable disease (reduction of tumor volume <50%) 
were considered to have disease control. Disease progression was defined as an increment of tumor volume 
greater than 25% during treatment. Hormone response to TMZ treatment was categorized as normalization 
(complete remission of hormone hypersecretion), partial response (reduction of at least 50 % compared to 
baseline but without normalization) and no response. Patients were censored at the date of the last follow-up, 
in order to calculate progression-free survival (PFS), disease control duration (DCD), and overall survival (OS) 
according to the Kaplan–Meier method.  
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3.2 Laboratory medicine and imaging  
 
Clinical Evaluation 
Clinical assessments were performed in the Endocrine Unit of the Padova University-Hospital. Participants 
were weighed and measured, wearing light clothing and no shoes, using a balanced beam scale and a vertical 
ruler: weight and height were recorded to the nearest 0.5 kg and 0.5 cm, respectively, then body mass index 
(BMI) was calculated (weight divided by height squared, kg/m2). Blood pressure was measured on the right 
arm three times in 5 minutes with a calibrated standard sphygmomanometer with the appropriate size cuff, 
after 5 minutes of resting in supine position according to the Korotkoff sounds, as recommended. Waist 
circumference was measured at the end of natural breaths at the midpoint between the top of the iliac crest and 
the lower margin of the last palpable rib. We considered hypertension if home systolic blood pressure levels 
were ≥130 mmHg or diastolic ≥85 mmHg (or if they were receiving antihypertensive treatment, a blood 
pressure ≥ 130/85 mmHg during medical treatment was sufficient to up-titrate or modify the usual therapy). 
Hyperandrogenism was considered either clinical (hirsutism, defined as an excessive terminal hair in 
androgen-dependent areas in women and a modified Ferriman–Gallwey score ≥8, alopecia and/or acne) and 
biochemical (not only testosterone, but also adrenal steroids precursors as 17-hydroxyprogesterone, 
androstenedione and DHEAS increased levels). 
At each visit, clinical and anthropometrical data were collected, electrocardiography was assessed and routine 
hematologic/blood/urinary biochemical measurements were performed in the Laboratory Medicine Unit of the 
Padova University-Hospital. Clinical data were reported in the web-based database of the University-Hospital 
of Padova, used as an electronic Case Report/Record Form (eCRF). Adverse events (AEs), both drug-related 
or suspected drug-related, were collected at each visit and reported in the eCRF according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, as recommended 
by Ethics Committee. 
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Hormonal Evaluation 
Hormones were measured in the same laboratory in the University-Hospital of Padova.  
From 1982 to 2004 serum cortisol was measured by RIA (DIA-Sorin Diagnostics, Saluggia, Italy) with intra- 
and inter-assay coefficient of variation (CV) values of 5.4 and 9.6% respectively; since 2004 serum cortisol 
assays are performed with a commercial chemiluminescence immunoassay with declared intra/interassay CV 
less than 7% and less than 9%, respectively (Immulite, Siemens).  
GH was measured with immunoradiometric assay (IRMA) and INSIK-5 (Sorin, Saluggia, Italy) with detection 
limits of 0.2 μg/L; IGF-1 was measured with radioimmunoassay (Nichols Institute, San Clemente, CA) for 
with a detection limit at least of 1.5 μg/L until 2003, then serum GH assays was performed with 
chemiluminescence by GH IMMUNOLITE 2000 (Siemens, the detection limit was 0.05 μg/L, intra- and 
interassay variation coefficients of 4.0% and 6.5%, respectively) and serum IGF-1 was measured by 
chemiluminescence with reagents supplied by DiaSorin Liaison (detection limit was 0.6 μg/L, with the intra- 
and interassay variation coefficients of 5.6% and 7.7%, respectively). 
 
For 24-hour urine collection to measure UFC levels, the patients were instructed to discard the first morning 
urine void and to collect all urine for the next 24 hours so that the morning urine void on the second day was 
the final collection. The sample was kept refrigerated from collection time until it was analyzed: a 10 mL 
aliquot sample was taken and centrifuged at 3000 rpm for 10 min at room temperature. Two µL formic acid 
and 50 µL of deuterated internal standard solution (d4-cortisol and d7-cortisone) were added to 500 µL of 
urine supernatant or calibrators. The solution was vortexed for 30 seconds and centrifuged at 16000g for 5 
minutes at room temperature. Twenty µL of the supernatant was added to 200 µL of 0.1% formic acid water 
solution and placed in the autosampler of the LC-MS/MS. UFC was measured, as is routine in our center, 
utilizing an Agilent HPLC series 1200 triple quadrupole mass spectrometer Agilent 6430 equipped with an 
Electrospray Ionization source in positive ionization mode (Agilent Technologies, Palo Alto, USA). The on-
line cleanup/enrichment was carried out using a cartridge Zorbax Extend-C18 2.1x12.5 mm, 5 μm particle size 
and the HPLC separation by a 4.6x50 mm, 1.8 µm particle size, analytical column Zorbax Eclipse XDB-C18 
(Agilent Technologies, Palo Alto, USA). Quantitative analysis was performed in the multiple reaction 
monitoring mode. The method was linear up to 625 nmol/L with a lower quantification limit of 5 nmol/L for 
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UFC, respectively. Within-run and between-run coefficients of variation were less than 5% and 6%, 
respectively. The mean recoveries were 106% for UFC. All the patients provided from two to five complete 
24-hour urine collections, the average values from all of the collections were used in the final analysis. The 
reference range utilized in our department, determined using the LC-MS/MS method described above, is 16-
170 nmol/24h for UFC108. 
 
Also LNSC is measured with a LC-MS/MS method. Patients were advised to soak for 2 or 3 minutes the 
absorbent cotton of Salivette ® device (Sarstedt, Numbrecht, Germany), samples were then stored at +4 °C. 
To avoid any source of food, blood, smoke or licorice contamination samples were collected at least 30 minutes 
before or two hours after taking a meal or drink and all participants brushed their teeth after saliva collection, 
and they were avoided smoking. After centrifugation we obtained at least 1 ml of saliva in all collections 
(repeating the procedures in few days if the patient did not provide adequate volume), then samples were stored 
at -20°C until assay. Each saliva sample or calibrator (300 μL), spiked with internal standard secondary mixed 
solution (30 μL), was applied to Oasis® HLB 1 mL solid phase extraction (SPE) cartridges (Waters, 
MA;USA), which had previously been equilibrated with 1 mL of methanol followed by 1 mL of water. After 
sample loading (250 μL), the washing step was performed with 500 μL water:methanol 80:20. 250 μL of 
methanol was then added and the eluate placed in the LC–MS/MS autosampler. The instrumentation consisted 
of an Agilent HPLC series 1200with a column oven, an autosampler, a binary LC pump and a degasser together 
with an additional isocratic pump with a switching valve for on-line SPE and a triple quadrupole mass 
spectrometer Agilent 6430 equipped with an Electrospray Ionization (ESI) source, operating in positive ion 
mode (Agilent Technologies, Palo Alto, USA). On-line purification was carried out by a Zorbax Extend-C18 
cartridge (2.1 × 12.5 mm, 5 μm particle size) and the HPLC separation by a Zorbax Eclipse XDB-C18 
analytical column (4.6 × 50 mm, 1.8 μmparticle size) (Agilent Technologies). Recovery tests. The mean 
recoveries of the three saliva samples were 101% for cortisol. The methodwas linear up to 55.4 nmol/L, low 
limits was 0.51nmol/L. ULN for LNSC is 2.6 nmol/L109. 
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Magnetic resonance 
All patients had serial magnetic resonance imaging (MRI). For our purposes, we considered the images at 
diagnosis, after the latest surgical procedure, at the time of starting medical therapy, then every 3 to 6 months 
during the first year of treatment and then every 6-12 months thereafter, as clinically indicated. All 
comparisons of images showing treatment-induced dimensional changes were drawn between the baseline 
MRI and the one obtained after the last dose. The PitNET volume of the was measured on contrast-enhanced 
T1 sequences: the area of the lesion was drawn manually on each slice, then the sum of all the areas was 
multiplied by the thickness of the slice according to the formula: ΣArea x (slice thickness + interslice gap). 
MRI scans were performed with a 1.5T or a 3T MRI (Achieva, Philips Medical Systems, Best, Netherlands), 
with a standard quadrature head coil. Each cerebral MRI underwent an operator-independent quantitative 
assessment performed with a free medical image viewer (Horos®) to automatically calculate the volume of 
the with PitNET. 
 
Body composition 
We measured body composition with DXA in all patients; we used the same Discovery W Hologic QDR 4500 
C densitometer (Hologic Inc., Waltham, MA, USA) at baseline (during active hypercortisolism, before any 
treatment to reduce cortisol levels) and during remission. The mean precision error (coefficient of variation) 
was 0.6%; reproducibility was 1.2%. Total body and trunk/abdominal fat/lean mass were measured by DXA; 
whereas the R1-box was manually defined as DXA subregion 4 cm (or 3 pixels) slice at the top of iliac crest. 
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3.3 Molecular analyses 
 
Primary cells everolimus treatments in non-functioning PitNET 
Primary cells derived from PitNET were cultured in vitro (5000 cell/well in a 96 wells plate) and treated with 
everolimus (0.1 and 1 µM, kindly provided by Novartis) for evaluating its pharmacological effect. After 72 
hours treatment the conversion of the tetrazolium dye MTT (Sigma-Aldrich) to formazan was ascertained 
following manufacturer protocol. After media removal and the addition of DMSO, the solution’s absorbance 
was measured at 550 nm – background subtraction set at 620 nm – with a microplate reader (Victor3 V 1420 
Multilabel 206 Counter, Perkin Elmer). To search for the TSC disease-causative variant – and possibly 
associate it with pituitary adenoma development – patient’s germline DNA was isolated from the peripheral 
blood and the genomic analysis of the entire TSC1 (NM_000368.4) and TSC2 (NM_000548.3) coding 
sequence and intronic boundaries was performed. Mutations were searched in in dbSNP and ExAC databases, 
the computational tools MutationTaster and Human Splicing Finder were used to predict the function.  
 
Evaluation of GIPR in GH-secreting PitNET 
Portions of the surgically removed specimens were fixed in 10% buffered formalin and then embedded in 
paraffin; standard sections stained with hematoxylin and eosin were used for diagnosis, whereas the presence 
of pituitary hormones was evaluated by standard immunocytochemical analyses. A second fragment for each 
tissue specimen was immersed in RNAlater (Ambion), kept at 4°C for 24 h and then stored at −20°C until 
RNA extraction. The remainder of each somatotropinoma was transferred to sterile cold complete culture 
medium and processed within 36 hours. The effect of GIP and SSA on GH secretion was examined in 
somatotropinoma-derived primary cells. Novartis Pharma AG kindly provided the SA Pasireotide (SOM230) 
and Octreotide (OCT), whereas GIP and Forskolin (FK) were purchased from Sigma-Aldrich. After seeding 
and incubation of primary cells at 37°C for 48–60 h, the medium was removed and replaced with 2% FBS 
DMEM containing GIP (100 nM), FK (10 μM), OCT (100 nM) or PAS (100 nM). Cells were incubated for 
further 6 h (GIP and FK) or 24 h (OCT and PAS) before the medium was recovered and frozen. 
Immunofluorescence for GIPR expression was performed on GH-sec PAs on conventional sections after 
deparaffinization in xylene, rehydration through graded alcohols to water and antigen retrieval (Dako) in 10 
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mM sodium citrate buffer (pH 6.0) for 10 min at 96°C. Sections of a normal human pancreas and of a GH-sec 
PA incubated with non-immune serum were used as positive and negative controls respectively. GIPR 
expression was visualized with a rabbit polyclonal antibody (kindly provided by Prof. Timothy Kieffer, 
University of British Columbia, Vancouver, Canada; O/N, 4°C, 1:250) and Alexa Fluor 594-labeled donkey 
antirabbit IgG secondary antibody (Life Technologies, 1:250). The tumor specimens collected in RNAlater 
were homogenized in a TissueLyser (Qiagen) in 1 mL of TRIzol reagent (Invitrogen) using a modified TRIzol 
protocol. RNA and DNA yields were determined on a NanoDrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA), and RNA integrity was tested with the Agilent 2100 Bioanalyzer (Agilent 
Technologies). Genomic DNA in the RNA was removed by DNAse, treating total RNA with Turbo DNA free 
kit (Ambion). RNA (500 ng) was reverse-transcribed with M-MuLV Reverse Transcriptase RNase H- 
(Euroclone, Pero, Italy) according to the manufacturer’s recommendations. The possible interaction between 
the GH/IGF-1 axis and the synthesis and/or secretion of GIP was investigated with murine enteroendocrine 
cell lines STC-1 (ATCC CRL-3254). Cells were cultured at 37°C and 5% CO2 in DMEM-low glucose 
(ECM0749, Euroclone) supplemented with 10% FBS, 3.7 g/L NaHCO3, 2 mM l-glutamine, 100 U/mL 
penicillin and 100 mg/mL streptomycin. Twenty-four hours before the experiment, STC-1 cells (1.75 × 105 
cells/well) were seeded into 12-well plates. Cells were transiently transfected with 2 μL of Lipofectamine 2000 
(Invitrogen) together with 1.6 μg of total DNA consisting of hGIP2.9kbluc (a kind gift from Prof. T Kieffer 
generated by cloning a 2.9-kb fragment of human GIP promoter (−2844 to +57 bp) upstream luciferase gene 
(17)) and pRL-TK (Promega) and incubated for 24 h. Cells were then treated for further 24 h with GH (from 
1 to 100 ng/mL), IGF-1 (from 0.1 to 100 ng/mL), insulin (100 nM) or the combination of FK and IBMX (10 
μM each) and the effect on GIP promoter activity was examined. All compounds used for cell treatments were 
purchased from Sigma-Aldrich. 
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3.4 Statistical analyses 
 
Proportions and rates were calculated for categorical data; continuous data were reported as means and 
standard error or median and interquartile range (IQR). Groups were compared by chi-square test for 
categorical variables and by the Wilcoxon rank sum test for quantitative variables. Wilcoxon signed-rank test 
for paired samples was used to compare data at baseline and during MET treatment. 
The database was managed and statistical analysis performed by SPSS 17 software package for Windows 
(SPSS, Inc., Chicago, IL, USA). Significance level was set as a p <0.05 for all tests. 
All procedures performed in studies involving human participants were in accordance with the ethical 
standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards.  
Informed consent was obtained from all individual participants included in the study. 
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4. Results             
4.1 medical treatment with everolimus in non-secreting PitNET  
 
(Publication I. Regazzo D, Endocrinol Diabetes Metab Case Rep 2018) 
A 62 years old Caucasian woman presented TSC, diagnosed after the recognition of cognitive disability and 
neurobehavioral abnormalities of her only 32 years old son. She presented the common TSC brain lesions at 
MRI (i.e. cortical tuber and right retinal hamartoma) without other typical TSC-related manifestations (e.g. 
renal, pulmonary, cardiac or skin lesions) and no family history of TSC. During the last twenty years she 
refused medical care, however in April 2012 she complaint headache: MRI scan showed a PitNET (diameter 
20x18x16 mm) with suprasellar extension, bilateral cavernous sinus invasion, shortened pituitary stalk and left 
optic nerve compression (Figure 3a). A hormonal study revealed normal thyroid and adrenal function, low 
gonadotropins (LH 3.5 U/L, range 11-61; FSH 13.5 U/L, range 35-150) and elevated prolactin (75.7-74-79 
µg/L, range 5-25, probably due to shortened pituitary stalk). After 4 months she underwent transsphenoidal 
endoscopic neurosurgery with complete tumor resection. Histologic evaluation demonstrated a uniform PAS-
positive basophilic adenoma with low proliferation index (MIB-1 <3%). Immunohistochemistry was positive 
for FSH and LH (figure 3b and 3c) and negative for ACTH, GH, prolactin and TSH. Clinical and histological 
findings were thus consistent with a silent gonadotroph PitNET. 
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Figure 3: a) Brain T1-weighted MRI after gadolinium injection: pituitary macroadenoma with suprasellar extension and 
bilateral cavernous sinus invasion; Immunohistochemical analysis of b) FSH (20X magnification) and c) LH (40X 
magnification) expression in the tissue slice of the silent gonadotroph PitNET d) and standard hematoxylin-eosin staining. 
 
 
 
 
Given the therapeutic potential of everolimus in TSC101 and PitNETs110 – both conditions present in our patient 
– primary cells derived from her pituitary adenoma were cultured in vitro (5000 cell/well in a 96 wells plate) 
and treated with everolimus (0.1 and 1 µM, kindly provided by Novartis) for evaluating its pharmacological 
effect. One µM treatment induced a significant 20% decrease in cell viability (p<0.05), confirming previous 
reported data110 (figure 4a). To search for the TSC disease-causative variant – and possibly associate it with 
pituitary adenoma development – patient’s germline DNA was isolated from the peripheral blood and the 
genomic analysis of the entire TSC1 (NM_000368.4) and TSC2 (NM_000548.3) coding sequence and intronic 
boundaries was performed. The analysis retrieved no disease-associated variants with the exception of the 
heterozygous intronic variant c.4006-71C>T found in TSC2 (figure 4b) and not present neither in dbSNP nor 
in ExAC databases. The computational tools MutationTaster and Human Splicing Finder both predicted a gain 
of a new splice site with consequent intron retention that was not confirmed by an in-vitro analysis of patient’s 
lymphocyte derived RNA. In addition, molecular analysis on archived paraffin-embedded pituitary tumoral 
tissues failed to identify both loss of heterozygosity in TSC2 locus (figure 4c), and protein expression reduction 
(figure 4c). 
Ceccato, Personalized medical treatment for pituitary adenoma, PhD thesis, pag 41 
 
 
Figure 4: a) Effects of everolimus treatment on pituitary tumor primary cells viability; c) Electropherograms centered on 
the c.4006-71C>T variant both in germline (upper panel) and tumoral (lower panel) DNA; d) immunohistochemical 
analysis of Tuberin expression (40X magnification) in the tissue slice of the silent gonadotroph PitNET (D93F12, XP® 
Rabbit mAb of Cell Signaling at 1:100 dilution after microwave antigen retrieval in 10mM citrate pH6.0). 
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4.2 Resistance to SSA in GH-secreting PitNET  
 
(Publication VII. Cannavò S, J Clin Endocrinol Metab. 2016; VI. Regazzo D, Eur J Endocrinol 2017) 
 
In a multicentric Italian collaborative study (supported by a grant of the Ministry of Education, University and 
Research of the Italian Government PRIN 2010/2011, cod- DI1112000360001), 210 consecutive acromegalic 
patients (79 men; mean age 47±10 years) were recruited at the Endocrinology Units of the University Hospitals 
of Messina (Sicily), Padua-Montebelluna (Veneto) and Ancona (Marche Region) up to 2015. Twenty-three of 
210 patients had lived for at least 20 years before diagnosis in HR areas, reported in the list of the areas of 
national interest for environmental risk (SIN) identified by the Department of Environment of the Italian 
Government on the basis of data collected by the Regional Agencies for Environment Protection (ARPAs). 
Data regarding the responsiveness to SSA treatment was evaluated in 142/187 and 18/23 cases, respectively.  
Heterozygous variants of AIP gene were detected in 7 of 210 patients (3.3%), two familial and five sporadic 
cases. A p.R304Q mutation (c.911G>A) and a p.R304 nonsense mutation (c.910C>T) was found in three and 
one patients, respectively, and a nucleotide substitution in the donor splice site of intron 3 (IVS3+1 G>A) in 
one patient, and a p.R16H change (c.47G>A) in the remaining two cases. Overall, rs2066853 (c.1661G>A) 
AHR polymorphism was found in homozygosis in one patient and in heterozygosis in 46 cases (22.4%). 
Moreover, heterozygous rs4986826 (c.1708G>A) AHR change was detected in six cases with rs2066853 AHR 
polymorphism (2.9%), one in homozygosis and five in heterozygosis. Among the 23 patients from HR areas, 
seven showed AHR polymorphisms (30.4%) and two were found with AIP mutations (8.7%). Mean IGF-I 
levels and pituitary tumor diameter were higher in these nine patients than in the other 14. These patients 
showed significantly higher IGF-I levels and tumor diameter at diagnosis also in comparison with those from 
non-polluted areas, regardless of whether they were carriers of AHR and/or AIP variants. SSA treatment 
normalized both IGF-I and GH levels in none of the mutated patients that live in HR areas, suggesting that 
acromegaly is more biochemically severe and resistant to SSA treatment in patients living in HR areas, 
especially if they also carry specific AHR and/or AIP gene variants, as summarized in figure 5.  
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Figure 5: Panel A, the percentage of patients who normalized IGF-I levels or reduced GH concentrations >50% or 
normalized both IGF-I and GH levels, stratified on the basis of HR or NP areas where they lived for >20 years before 
diagnosis and on the basis of the occurrence (VAR+) or not (VAR-) of AHR and/or AIP variants. Panel B, the differences 
of IGF-I levels, expressed as x ULN at baseline and after 6 months of treatment in the four groups of patients. 
 
 
 
 
 
Considering GIP and GIPR pathway in GH-secreting PitNET primary culture, samples were divided into two 
distinct subgroups: the first comprises 15 samples expressing GIPR within the range for normal pituitaries 
(GIPR-L; from 1.6x10−4 to 1.7x10−2, mean 2.9x10−3), and the second comprises 10 samples expressing GIPR 
at significantly higher levels (GIPR-H; from 0.02 to 0.27, mean 0.13±0.08). By immunofluorescence we 
confirmed the high GIPR expression in the adenoma sections in the latter cases, both membrane and 
cytoplasmic immunoreactivity. Co-localization of red and green staining in the same cell confirmed that GIPR 
is expressed in GH-secreting tumor cells (figure 6). 
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Figure 6: Representative immunofluorescence staining of a GH-secreting PitNET with high GIPR expression. (A) GH is 
visualized in the green immunofluorescent channel, whereas (B) GIPR in the red one. (C) Co-localization of red and green 
staining in the same cell confirms that GH-secreting tumor cells express GIPR. Cells are counterstained with Hoechst 
(blue) to mark nuclei. (D) Positive control is a section of a normal human pancreas. Immunofluorescent images are at 
100× magnification. 
 
 
 
 
To definitively confirm the link between GIP/GIPR and the GH-PI, GH-secreting PitNET derived primary 
cultures have been established and cells were treated with GIP. As shown in figure 7A, 8/10 GIPR-H cases 
significantly responded to GIP. 
 
Figure 7: GH-sec PA-derived primary cultures responsiveness to different stimuli. (A) Cell cultures have been treated 
with 100 nM GIP or vehicle and GH secretion has been evaluated. The level of GH secretion was expressed as relative 
percentage to vehicle-treated tumor cells 
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4.3 Long-term medical treatment in acromegaly and risk of 
hypopituitarism  
 
(Publication VIII. Ceccato F, Horm Metab Res 2016) 
 
Our cohort of patients with acromegaly is described in table 5, sorted by the presence of Central Adrenal 
Insufficiency (CAI). The overall prevalence of CAI in our cohort was 22% (21 out of 97 patients), and it was 
found unrelated to age, gender, age at diagnosis, duration of follow-up or cavernous sinus invasion, although 
CAI patients had larger adenomas. Two of our patients were excluded from further analyses because presented 
CAI at acromegaly diagnosis. 
 
Table 5: Clinical characteristics of acromegalic patients with and without central adrenal insufficiency (CAI). Data are 
shown as medians (IQR) or percentages. 
 
 
Characteristic With CAI (n = 21) 
Without CAI 
(n = 76) p 
Age at acromegaly diagnosis (years) 41 (33-51) 49 (38-57) 0.107 
Age at time of study (years) 64 (46-67) 60 (51-70) 0.673 
Follow-up for acromegaly (months) 192 (84-264) 108 (60-204) 0.122 
Female (%) 14/21 (67) 48/81 (59) 0.536 
Adenoma max diameter (mm) 21 (15-23) 15 (10-16) 0.01 
Pituitary macroadenoma (%) 11/13 (85) 44/65 (68) 0.324 
Cavernous sinus invasion (%) 19/21 (90) 57/81 (70) 0.225 
Pituitary TNS (%) 19/21 (91) 55/81 (68) 0.053 
Pituitary TNS (without RT) 10/12 (83) 47/72 (65) 0.322 
SSA (%) 14/21 (67) 50/81 (62) 0.802 
SSA as primary treatment  2/2 (100) 19/21 (90) 0.397 
SSA after TNS 12/19 (63) 31/55 (56) 0.605 
Dopamine agonist (%) 4/21 (19) 17/81 (21) 1.000 
Pegvisomant  5/21 (26) 15/81 (27) 0.935 
Pituitary RT (%) 9/21 (43) 9/81 (11) 0.001 
 
 
Considering treatments, in our cohort 23 acromegalic patients were treated with primary medical therapy (21 
with SSA, 2 with DA; median 8 years; IQR 3.5-12). The other 74 patients underwent TNS (51 once), and 
among surgical patients 24 assumed medical treatment before TNS (for 3-6 months). Surgical failure was 
observed in 39% of patients, who then assumed medical therapy (SSA, DA or pegvisomant, alone or 
combined), 6 repeated TNS and 17 were irradiated (treatment strategies are summarized in figure 8). 
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Figure 8: Study design and CAI distribution among the various treatments  
 
 
 
As regards medication, the use of SSA, DA or pegvisomant was similar for patients with and without CAI, for 
both primary and post-TNS therapy: the CAI onset rate was lower after primary medical treatment than after 
repeat TNS (p=0.002) or RT (p=0.003). Patients who underwent TNS without any subsequent RT revealed no 
HPA axis damage (p=0.3), whereas 50% of patients who repeated TNS developed CAI (p=0.015 versus 
patients who had TNS only once).  In our cohort, 9 out of 17 of irradiated patients (after TNS) developed CAI: 
after conventional RT in 8/13 cases, and after radiosurgery in 1/4 (p=0.2). Pituitary irradiation was associated 
with a higher risk of developing CAI than TNS plus medical therapy, as shown in figure 9 (Mantel-Cox log 
rank p=0.035 for TNS+RT vs TNS, and p=0.034 for TNS+RT vs medical treatment). Overall, acromegaly was 
controlled in 80% of our patients (>90% after ≥5 years of follow-up), irrespective of adenoma size (73% of 
macro-adenomas and 90% of micro-adenomas, p=0.778), use of TNS (81% after surgery versus 75% without 
TNS, p=0.585), medical treatment (75% with versus 87% without medical treatment, p=0.207), or RT (94% 
with versus 77% without RT, p=0.082). The acromegaly control rate was similar for patients given RT after 
TNS and those who underwent surgery alone (90% vs 78%, p=0.118). Acromegaly control was also similar in 
patients with and without CAI (86% vs 78%, p=0.423), also taking any use of TNS or RT into account. 
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Figure 9: Life-table analysis indicating probabilities of initially normal HPA axis remaining normal in our cohort by type 
of treatment. 
 
 
 
In a binomial logistic regression analysis performed to calculate the HR of each treatment inducing CAI, RT 
and repeat TNS carried the highest risk (Table 6), whereas primary or secondary medical treatment were 
unrelated to the onset of CAI. Among the 17 patients irradiated after TNS, the CAI rate was statistically similar 
among the 13 patients who had only one TNS (6 developed CAI, 46%) and among the 4 subjects who had 
repeat TNS before receiving RT (3 developed CAI, 75%, p=0.312). The rate of other pituitary deficiencies was 
higher for the acromegalic patients with CAI than for those judged to have a normal HPA axis (p=0.001), 
especially among the irradiated patients (p=0.001). 
 
 
 
Table 6: Binomial logistic regression analyses to calculate the role of several variables in inducing CAI. HR: hazard ratio; 
CI: confidence interval for HR. 
 
 
 p HR (95% CI) 
Gender 0.404 1.71 (0.48-6.05) 
Cavernous sinus invasion 0.452 2.41 (0.24-23.93) 
Medical treatment 0.368 1.81 (0.49-6.59) 
TNS 1.00 0.00 (0.00-0.02) 
Repeat TNS 0.037 5.84 (1.11-30.62) 
Radiotherapy 0.044 4.01 (1.04-15.46) 
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4.4 Metyrapone in ACTH-secreting PitNET (Cushing’s Syndrome)  
 
(publication II. Ceccato F, Endocrine 2018) 
 
31 patients with CS were enrolled: 20 with CD, 6 with ectopic CS (EAS) and 5 with adrenal CS (ACS). Median 
MET treatment duration was 9 months (IQR 3-12 months). All 31 patients were treated for at least 1 month 
(as indicated in inclusion criteria); 25 patients completed 3 months and 18 patients 6 months of treatment. 
Considering long-term follow-up, 13 and 6 patients completed 12 and 24 months of consecutive MET 
monotherapy, respectively. Median MET dose at last visit was 1000 mg (IQR 500-1500).  
At baseline all 31 patients presented increased mLNSC; normal mUFC levels were observed in 5 cases (3 of 
them presented one out of 3 UFC measurement >ULN). mUFC and mLNSC levels decreased after the first 
month of treatment: median -67% (IQR 55-82) and -57% (IQR 26-80) from baseline, respectively. Data of CD 
are depicted in table 7. The cortisol reduction continued also in the third month of treatment: median -70% 
(IQR 54-91) and -63% (IQR 46-83) from baseline (median -43% and -28% from month 1), for mUFC and 
mLNSC respectively, as depicted in figure 1. Considering all patients, 3 months of treatment were able to 
normalize mUFC in 68% of patients (64% considering those with mUFC >ULN at baseline, n=14/22); mUFC 
levels dropped after one and 3 months, achieving a sustained normalization that continued up to 12 and 24 
months. MET was able to normalize mUFC levels in the first month of treatment in patients with mild, 
moderate and severe hypercortisolism, otherwise 3 to 6 months of treatment were needed to control cortisol 
secretion in patients with very severe hypercortisolism. Considering patients with severe hypercortisolism at 
baseline (n=10), median mUFC and mLNSC reduction was -86% (IQR 80-92) and -80% (IQR 70-88) after 1 
month of treatment, respectively. Overall 71% of patients normalized mUFC levels at the last visit (62% 
considering those with mUFC >ULN at baseline), independently from the severity of hypercortisolism at 
baseline. 
The MET efficacy to recover cortisol rhythm (37% of patients presented mLNSC <ULN at last visit) was 
lower than that to normalize cortisol excretion (70% of patients presented mUFC <ULN at last visit). In the 
long term-follow-up mean mLNSC levels were still >ULN, albeit reduced from baseline. None of the CS 
patients presented with normal cortisol rhythm at baseline: the complete recovery of cortisol rhythm at the last 
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available visit was obtained especially in patients with normal mUFC or mild hypercortisolism at baseline. 
Patients with severe or very severe hypercortisolism required a longer treatment (from 3 to 6 months) to reduce 
mLNSC levels. Short-term MET therapy (1 month) was able to reduce mUFC and mLNSC; contrariwise, after 
at least 3-6 months, mUFC normalized in 70% of patients, and half patients showed both mUFC and mLNSC 
<ULN after long-term treatment (12-24 months, as depicted in figure 2). MET treatment was effective before 
surgery: mUFC and mLNSC median reduction was -80% (IQR 63-94) and -75% (IQR 52-92) respectively 
from baseline (both p<0.01, median preoperative therapy 3 months). 
Regarding different type of CS, we found that EAS patients were older than CD and ACS, and presented with 
higher levels of mUFC and mLNSC than CD. MET doses and cortisol levels at last visit were similar among 
subtypes of CS, nevertheless MET was used as a long-term therapy especially in CD. MET was used before 
surgery especially in EAS (5 out of 6) and ACS (5 out of 5) compared to CD (6 out of 20, both p<0.01). The 
outcome of MET therapy in CD was similar when used before or after surgery, despite different follow-up. 
Clinical and hormonal data were similar considering baseline and last visit in CD patients (table 2), but mUFC 
normalization rate was higher in CD patients treated with MET after surgical failure (12 out of 14 patients, 
86%) than those treated with MET before surgery (1 out of 6 cases, 17%, p=0.007). 
An “escape” from MET treatment was observed in 3 patients. Their mUFC levels were normalized after 6 
months of therapy (and in 2 cases also mLNSC were <ULN), and the escape was observed before the next 
scheduled visit (9 months after MET therapy), associated with a worsening of cortisol-related signs and 
symptoms. We decided not to increase MET in these 3 patients with CD: one performed the first pituitary 
surgery, the second repeated pituitary intervention (achieving remission), and the third performed stereotactic 
radiotherapy (her cortisol levels are now controlled with cabergoline and ketoconazole).  
On the whole, MET was well tolerated, and none of the patients reported severe side-effects (As reported in 
the CTCAE version 4.0). Two patients discontinued MET after the first month of therapy (despite both 
achieving normal UFC levels) for peripheral edema, nausea, asthenia (one patient) and allergic dermatitis with 
arthralgia (the other one). None of the patients developed adrenal insufficiency during MET treatment. 
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Table 7: biochemical and clinical results in patients with ACTH-secreting PitNET (CD). Metyrapone (MET) therapy was 
used as primary medical therapy (n=6) or after surgical failure (n=14, 9 with persistent and 5 with recurrent 
hypercortisolism after neurosurgery); data are expressed as mean and standard error. Number of patients is represented 
in brackets. MET dose and months of MET treatment are indicated with median and interquartile range. mUFC: mean of 
3 UFC collections; mLNSC: mean of 2 LNSC collections; BMI: Body Mass Index; BP: blood pressure. 
 
 
 
As depicted in figure 10, MET treatment was effective to reduce quickly UFC and LNSC levels in the first 
month of treatment (p <0.005 with baseline for all visits), achieving UFC normalization after 3 months of 
therapy. Moreover, extended MET treatment (up to 12-24 months) was able to maintain the achieved results 
on cortisol excretion. All patients are summarized in figure 11. 
 
Table 8: UFC and LNSC levels indicated in figure 10 in baseline and subsequent visits. 
 
 
UFC 
baseline 
UFC 
1_month 
UFC 
3_months 
UFC 
6_months 
UFC 
12_months 
UFC 
24_months 
Mean nmol/L 1393 344 167 180 167 104 
Standard deviation 1951 500 206 239 93 89 
Standard error 461 110 43 60 26 40 
 LNSC LNSC LNSC LNSC LNSC LNSC 
Mean nmol/L 19.8 7.5 5.4 2.8 4.5 4.2 
Standard deviation 17.0 6.6 6.8 2.0 4.5 3.7 
Standard error 3.9 1.7 1.7 0.6 1.4 1.9 
  
  
MET before surgery 
(n=6) 
MET after surgical failure 
(n=14) p 
age (years) 40 (4) 47 (4) 0.207 
months of MET treatment 3 (3-6) 12 (12-24) 0.045 
MET dose (mg)  
baseline 750 (500-750) 500 (500-750) 0.659 
last visit 1000 (500-1250) 1000 (500-1250) 0.779 
mUFC (nmol/24h)  
baseline 1769 (1248) 558 (228) 0.026 
last visit 204 (36) 165 (69) 0.091 
mLNSC (nmol/L)  
baseline 29.6 (9.3) 10.9 (2.5) 0.072 
last visit 5.5 (2.6) 4.2 (0.8) 0.981 
weight (kg)  
baseline 80.5 (7.8) 73.9 (3.8) 0.444 
last visit 78 (6.7) 76 (3.7) 0.718 
BMI (kg/m2 )  
baseline 26.9 (1.7) 28.9 (1.7) 0.547 
last visit 26.5 (1.9) 29.5 (1.6) 0.391 
waist (cm)  
baseline 102 (4) 103 (4) 0.904 
last visit 101 (5) 103 (5) 0.893 
systolic BP (mmHg)  
baseline 136 (3) 135 (5) 0.968 
last visit 142 (6) 140 (5) 0.878 
diastolic BP (mmHg)   
baseline 90 (3) 82 (2) 0.718 
last visit 92 (5) 90 (3) 0.721 
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Figure 10: mean UFC levels at each scheduled visit. Bars indicate standard error. 
 
 
 
 
 
 
 
 
T
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Figure 11: Individual response to MET therapy in each patient, considering baseline levels of mUFC and LNSC (related 
to ULN). Individual MET dose at baseline and at last visit is indicated between the graphs. 
 
 
 
MET is able to normalize UFC levels quickly (in the first month, see figure 12) in the most part of patients 
with mild and moderate severe, otherwise in patients with severe or very severe hypercortisolism 3 to 6 months 
are needed to control cortisol secretion. 
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Figure 12: spaghetti plot of response to MET therapy (each line is a patient) according to severity of hypercortisolism at 
baseline. Dotted black line = normal UFC; red line = mild hypercortisolism; blu line = moderate hypercortisolism; red 
line = severe hypercortisolism; purple line = very severe hypercortisolism. UFC is depicted in a logarithmic base 2 scale. 
 
 
 
Finally, we observed that disease control (in those patients with increased UFC) at the last available visit was 
similar considering baseline severity of hypercortisolism, as depicted in figure 13. 
 
 
Figure 13: Patients that normalize UFC levels at last visit after MET therapy, according to severity of hypercortisolism 
at baseline visit 
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MET treatment was effective to reduce quickly LNSC levels (as reported in figure 14), nevertheless it was not 
able to restore completely circadian cortisol rhythm in all patients, as depicted in figure 15. 
 
Figure 14: response to MET therapy (each line is a patient) according to severity of hypercortisolism at baseline. Blu 
line = moderate hypercortisolism; red line = severe hypercortisolism; purple line = very severe hypercortisolism. 
 
 
 
Figure 15: Patients that normalize LNSCC levels at last visit after MET therapy, according to severity of hypercortisolism 
at baseline visit 
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Before enrolment, 24/31 patients presented hypertension (normalization of blood pressure levels was achieved 
in 10 subjects). During MET therapy, 2 normo-tensive patients presented an increase of blood pressure levels, 
controlled with medical monotherapy (ramipril 10 mg in one case and potassium canrenoate 100 mg in the 
other); 5/24 hypertensive patients needed an up-titration of their treatment and 4/24 hypertensive patients 
stopped their anti-hypertension drug during the study. Overall, we did not observe any increase of systolic or 
diastolic blood pressure (see figure 16). Potassium levels were lower at baseline in EAS than in CD (4 EAS 
and 3 CD patients presented with potassium <3.5 mEq/L). At last visit, most of patients (26/31) presented with 
normal potassium levels, and none with severe hypokalemia (potassium <2.5 mEq/L). Before enrollment 11 
patients presented with impaired fasting glucose or over diabetes, and after MET 7 patients reduced the dose 
or the number of anti-diabetic drugs. 
 
Figure 16: mean systolic blood pressure (solid line) and diastolic blood pressure (dotted line) after MET therapy. Bars 
indicate standard error. 
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We studied, in 3 patients, the effect of combined PAS and MET treatment. 
• Patient 1: female, 32 years, failure of combination therapy: nowadays treated with an experimental 
compound (LCI699). Figure 17, A 
• Patient 2: female, 51 years, efficacy of combination therapy. Figure 17, B 
• Patient 3: female, 46 years, efficacy of combination therapy. Figure 17, C 
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4.5 Differential effects of medical treatment in Cushing’s Syndrome 
 
(publication V. Ceccato F, Horm Metab Res. 2017, III. Barbot M, Endocrine 2018) 
 
Currently few papers studied body composition changes in adult patients with CS after achieving remission. 
Therefore, it is not yet clear whether body composition is normalized after remission of hypercortisolism. 
Moreover, there are no published data regarding the effects of different treatments on body composition, as 
surgery or medical therapy. Our study aimed to prospectively evaluate body composition changes with DXA 
in patients with active hypercortisolism and during remission phase, considering different therapeutic plan. 
We collected data at baseline (before treatment) and at last available follow-up during remission, mean 
observation time was 32 months (range 13-86). Overall, as presented in Table 8, patients reported a decrease 
of BMI and waist circumference after achieving remission (respectively mean -7.6% and -4.5%), coinciding 
with an improvement in blood pressure and cholesterol levels. In total body DXA scans we found a decrease 
in total mass (-7.5%), due to a reduction of both lean and fat mass (respectively -3.3% and -12.8%). Lean mass 
levels (also considering bone mineral content) decreased in total body and R1 box, whereas they did not change 
at trunk levels. Decrease in fat tissue (both mass and percentage) was observed in total body, trunk and R1 box 
(respectively -14.4% and -17%). Body composition of CS after remission was similar to matched controls, 
especially fat mass in all the considered DXA scans (total body, trunk and R1 box). 
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Table 8: Anthropometric and body composition measurements in the whole cohort of 23 CS patients. a = p < 0.05 active 
CS vs controls; b = p < 0.05 remission CS vs controls; BMC = bone mineral content 
 
 
 
active CS remission CS p  (active vs remission) controls 
Anthropometry 
age (years) 46.6 ± 12.2 51 ± 13.4 0.0003 46.7 ± 8.9 
BMI (kg/m2) 27.6 ± 5.3 25.3 ± 3.9 0.0003 26.4 ± 4.6 
waist (cm) 102 ± 14 97 ± 12 0.0201 - 
hypertension (n) 17 out of 23 (74%) 9 out of 23 (39%) 0.0047 - 
diabetes (n) 8 out of 23 (35%) 10 out of 23 (43%) 0.3173 - 
glucose (mg/dL) 123.3 ± 58 106.2 ± 31.7 0.5953 - 
total cholesterol (mg/dL) 233.4 ± 44.3 209.3 ± 54.2 0.0132 - 
metabolic syndrome (n) 8 out of 23 (35%) 3 out of 23 (13%) 0.0588 - 
DXA total body 
fat (g) 28855 ± 11198 24148 ± 8620 0.0052 23498 ± 8179 a 
fat (%) 37.5 ± 8.9 34.6 ± 8.2 0.0249 33.8 ± 7.9 a 
lean (g) 44060 ± 7221 42660 ± 7678 0.0207 43363 ± 8857 
lean + BMC (g) 46047 ± 7479 44584 ± 7948 0.0171 45439 ± 9154 
total mass (g) 74902 ± 15508 68731 ± 12537 0.0002 68856 ± 13128 
DXA trunk 
fat (g) 15384 ± 6390 12398 ± 4948 0.0041 11520 ± 4979 a 
fat (%) 38.8 ± 9.6 34.9 ± 8.4 0.0155 32.9 ± 10.7 a 
lean (g) 22401± 3703 21766 ± 4109 0.618 21405 ± 3986 
lean + BMC (g) 22922 ± 3724 22289 ± 4123 0.385 21934 ± 4056 
total mass (g) 38262 ± 8920 34687 ± 7447 <0.0001 33454 ± 7385 a 
DXA R1 box 
fat (g) 1747 ± 796 1375 ± 658 0.0046 1182 ± 566 a 
fat (%) 42.8 ± 10.6 38.8 ± 10.3 0.0289 35.5 ± 12.4 a 
lean (g) 2109 ± 363 1974 ± 387 0.0046 1760 ± 327 a,b 
lean + BMC (g) 2131 ± 365 1999 ± 949 0.0046 1852 ± 345 a 
total mass (g) 3878 ± 1097 3374 ± 949 0.0003 3038 ± 812 a 
 
 
At baseline, the 2 groups of active CS patients divided for remission (surgical or pharmacological) presented 
similar UFC and LNSC levels (respectively p=0.557 and p=0.607) and DXA data (described in table 9, for fat 
mass p=0.305, p=0.643 and p=0.734 respectively in total body, trunk and R1 box scan). Mean remission 
follow-up was 39 months in the surgical and 20 months in the pharmacological group (p=0.039). Considering 
last available follow-up, UFC levels were similar during remission of CS (respectively after surgery and 
pharmacological treatment: mean 46 vs 80 nmol/24, p=0.27), otherwise LNSC levels were higher during 
medical treatment (mean 1±0.2 vs 1.8±0.4 nmol/L, p=0.043), despite normal in every patients, since it was an 
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inclusion criteria. UFC and LNSC levels were similar at baseline, as well as at last available follow up after 
pharmacological treatment, considering pituitary-directed drugs (n=6) and steroidogenesis inhibitors (n=3).  
After surgical remission of CS we confirmed the reduction of BMI (-8.3%), waist circumference (-7.4%), 
glucose levels and the decrease of hypertension and metabolic syndrome, as detailed in Table 2 and figure 18. 
The decrease of fat mass and percentage after surgery (-17.3%) was confirmed as well as in the overall 
remission group, considering total body, trunk and R1 box (depicted in figure 18): at the end of the study body 
composition parameters were similar to healthy matched controls. On the other hand, the reduction of fat mass 
achieved with pharmacological treatment was inferior, although body composition was similar to controls. 
Glucose levels increased after pharmacological remission of hypercortisolism, especially in the 6 patients 
treated with pasireotide; among them, three developed overt diabetes and were treated with insulin (in one 
patient) and with the combination of metformin+sitagliptin (in two subjects).  
 
 
Figure 18: DXA results of fat mass in total body (panel A), trunk (panel B) and R1 (panel C) box during active 
hypercortisolism and remission of CS, divided by treatment. 
 
 
To the best of our knowledge, there is only one study evaluating the effect of short-term medical therapy in 
clotting factors111, but no data are available on the effects of long-term treatment with cortisol lowering 
medication on this aspect. Therefore, we evaluated the effectiveness of long-term therapy with PAS 600 μg 
twice daily in hemostatic alterations in patients with active CD. Despite significant reduction in UFC levels 
(up to half patients, more than the III-phase trial68) none of the coagulative parameters explored showed any 
significant changes during the therapy, neither at 6 nor 12 months of therapy. No significant differences in 
coagulative profile were observed between patients with normal and elevated UFC at 6 and 12 months. 
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Table 9: Anthropometric and body composition measurements in CS patients, considering treatment strategy.  pCS: active CS vs remission CS; pcontrols: remission CS vs controls. 
 
 SURGICAL TREATMENT (n =14) PHARMACOLOGICAL TREATMENT (n =9) 
 active CS remission CS pCS pcontrols active CS remission CS pCS pcontrols 
Anthropometry 
BMI (kg/m2) 28.1 ± 5.8 25.5 ± 3.9 0.0085 0.353 26.9 ± 4.8 25 ± 4.2 0.0547 0.730 
waist (cm) 106 ± 12 98 ± 12 0.004 - 96 ± 15 96 ± 13 0.9453 - 
hypertension (n) 11 out of 14 (79%) 5 out of 14 (36%) 0.0143 - 6 out of 9 (67%) 4 out of 9 (44%) 0.1573 - 
diabetes (n) 5 out of 14 (36%) 4 out of 14 (26%) 0.3173 - 3 out of 9 (33%) 6 out of 9 (67%) 0.0833 - 
glucose (mg/dL) 138 ± 69 94 ± 30 0.001 - 100 ± 24 125 ± 68 0.0391 - 
total cholesterol (mg/dL) 233 ± 30 210 ± 45 0.0681 - 234 ± 62 208 ± 46 0.1641 - 
metabolic syndrome (n) 6 out of 14 (43%) 2 out of 14 (14%) 0.0455 - 2 out of 9 (22%) 1 out of 9 (11%) 0.5637 - 
DXA total body 
fat (g) 30844 ± 10484 24937 ± 8010 0.0067 0.598 25762 ± 12188 22920 ± 9863 0.4258 0.818 
fat (%) 40 ± 6.1 35.9 ± 6.8 0.0107 0.385 33.6 ± 11.4 32.6 ± 10 0.8203 1 
lean (g) 43005 ± 7025 41853 ± 7303 0.1937 0.571 45700 ± 7632 43917 ± 8518 0.0195 0.645 
lean + BMC (g) 44937 ± 7161 43730 ± 7492 0.2412 0.533 47772 ± 8061 45912 ± 8903 0.0195 0.618 
total mass (g) 75781 ± 16030 68666 ± 12503 0.0067 0.965 73534 ± 15503 68833 ± 13349 0.0391 0.969 
DXA trunk 
fat (g) 16767 ± 5990 12774 ± 4985 0.0009 0.457 13232 ± 6739 11812 ± 5130 0.7344 0.818 
fat (%) 41.8 ± 5.3 36.1 ± 6.9 0.0031 0.270 34.2 ± 13.1 33.1 ± 10.4 0.7344 0.788 
lean (g) 22200 ± 3780 21345 ± 4022 0.104 0.965 22719 ± 3781 22422 ± 4398 0.4961 0.489 
lean + BMC (g) 22736 ± 3769 21892 ± 3999 0.0785 0.975 23211 ± 3861 22907 ± 4477 0.4258 0.465 
total mass (g) 39432 ± 9289 34666 ± 7904 0.0002 0.642 36443 ± 8514 34718 ± 7141 0.25 0.645 
DXA R1 box 
fat (g) 1845 ± 663 1401 ± 486 0.0107 0.214 1594 ± 992 1336 ± 897 0.25 0.848 
fat (%) 45.7 ± 6.3 41.3 ± 7.4 0.0479 0.115 38.3 ± 14.5 34.9 ± 13.3 0.4258 0.939 
lean (g) 2102 ± 353 1908 ± 368 0.0031 0.223 2120 ± 390 2077 ± 415 0.5703 0.041 
lean + BMC (g) 2123 ± 353 1933 ± 370 0.0023 0.511 2145 ± 404 2102 ± 421 0.5703 0.151 
total mass (g) 3968 ± 938 3333 ± 711 0.0012 0.247 3739 ± 1357 3437 ± 1285 0.2031 0.539 
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4.7 Early recognition in aggressive PitNET  
 
(Publication IV. Ceccato F, Acta Neurochir, 2017) 
 
Considering a data lock in middle 2017, we collected only patients with at least 2 years of follow-up after 
presentation and intervention (in order to analyse solid and reliable data). We considered 102 patients with 
aggressive PitNET using the combined clinical-radiological-pathological definition proposed in table 1 in the 
introduction. This consists in 18% of the whole cohort, 57 male and 47 female, median age was 49 years (IQR 
42-61), median age at diagnosis was 43 years (IQR 35-54) and median presumed onset of disease was 42 years 
(IQR 30-53). We identified ACTH secretion in 14 patients (17%), GH in 18 cases (20%), PRL in 23 patients 
(13%) and 47 cases resulted non-functioning PitNET (31%). As reassumed in table 10, patients with NFPA 
were older at diagnosis and disease onset than those with ACTH- (respectively p=0.008 and p=0.001), GH- 
(p=0.005 and p=0.001) and PRL-secreting adenomas (both p=0.001). Median follow-up (5 years, IQR 2-9) 
was similar among all patients. Furthermore, patients with PRL- were diagnosed earlier than those with GH-
secreting adenoma (p=0.038) and the percentage of males was greater among PRL- than ACTH- (p=0.038) 
and GH-secreting adenomas (p=0.031). 
Overall 75% of patients with aggressive pituitary adenoma presented a radiological diagnosis of invasion; as 
depicted in table 3, we observed a higher incidence of invasiveness in patients with GH-, PRL- and non-
secreting adenoma (respectively p=0.017, p=0.039 and p=0.014). Most of them (69%) presented cavernous 
sinus invasion (CSI), especially patients with GH-, PRL- and NFPA than ACTH-secreting adenoma 
(respectively p<0.001, p=0.010 and p=0.002). Remission rate was similar in patients with an invasive 
adenoma, irrespective of hormonal secretion type. 
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Table 10: clinical characteristic of disease onset and follow up of patients with aggressive PitNEt sorted by secretion; 
data are reported as median and interquartile range (IQR). M: male; F: female.  
 
 Gender  
(M/F) 
Age 
(years) 
Age of 
diagnosis (years) 
Age of presumed 
onset (years) 
follow-up  
(years) 
ACTH (n=14) 5/9 48 (38-53) 41.5 (33-51.3) 34.5 (23-50) 5 (2-7.3) 
GH (n=18) 7/11 46 (42-53) 40.5 (34.5-51) 39 (30.2-45.8) 5 (2.8-9) 
PRL (n=23) 17/6 42 (32-47) 34 (24-41) 30 (23-38) 6 (4-10) 
Non secreting (n=47) 27/20 61 (50-69) 52 (43-64) 51 (40-64) 5 (2-10) 
Total (n=102) 44/46 49 (42-61) 44 (35-53) 42 (30-52) 5 (3-9) 
 
 
We observed a pathological report consistent with atypical adenoma in 24% of patients, as reassumed in table 
11. Considering only those patients with an atypical pituitary adenoma (n=23), remission rate ranged from 
30% to 80%, and was higher in patients with PRL- than in those with NFPA (83% vs 37%, p=0.036), 
irrespective of CSI or size of the adenoma. In our series 33% of surgical specimens revealed MIB-1 >3%, with 
higher prevalence in ACTH- and PRL- than in NFPA (both p=0.041); MIB-1 was higher in ACTH- and PRL- 
compared with GH-secreting adenoma (near significance, respectively p=0.086 and p=0.079). The rate of 
radiological invasion was similar among typical and atypical adenomas.  
Among 44 patients with NFPA, 21 patients (48%) presented a silent adenoma with positive immunostaining 
for ACTH (n=6), GH (n=1), PRL (n=2) and FSH/LH (n=12). The rate of atypical adenomas, their radiological 
invasion and their remission rates (after therapy) were similar among patients with silent compared to those 
with null-cell adenomas. Atypical adenomas, invasiveness and remission rates were also similar comparing 
patients with ACTH-silent or FSH/LH-silent and null-cell adenomas. 
 
 
Table 11: radiological and pathological criteria of aggressiveness in patients with aggressive PitNET. RR: remission rate; 
CSI: cavernous sinus invasion. Atypical adenoma is considered as that proposed by WHO 2004 (increased or atypical 
mitoses, Ki67 >3%, positive p53)  
 
 Invasive 
Adenoma n 
(%) 
RR in invasive 
adenoma  
(%) 
 
CSI (%) 
RR in 
CSI (%) 
Atypical 
Adenoma 
(%) 
RR in atypical 
Adenoma (%) 
ACTH (n=14) 6/14 (43) 2/6 (33) 3/6 (50) 1/3 (33) 5/14 (36) 4/5 (80) 
GH (n=18) 15/18 (83) 7/15 (47) 12/15 (80) 5/12 (42) 4/18 (22) 2/4 (50) 
PRL (n=23) 18/23 (78) 9/18 (50) 12/18 (67) 7/12 (58) 6/20 (30) 5/6 (83) 
Non secreting (n=47) 38/47 (81) 14/38 (37) 26/38 (68) 10/26 (38) 8/44 (18) 3/8 (37) 
Total  77/102 (75) 32/77 (42) 53/77 (69) 23/53 (43) 23/96 (24) 14/23 (61) 
 
 
Surgery was the most performed treatment among all patients, especially in those secreting ACTH or GH (see 
table 12). Considering all cases, surgical remission rate was 24% (23 out of 96), higher in ACTH- than in GH- 
Ceccato, Personalized medical treatment for pituitary adenoma, PhD thesis, pag 63 
and PRL-secreting adenoma (respectively p=0.049 and p=0.026). Overall 22% of patients were submitted to 
radiotherapy (in 18 subjects conventional and 4 radiosurgery with cyberknife), with a remission rate of 43% 
after median 3 years. Radiotherapy was more applied to patients with ACTH- than GH-secreting adenoma 
(p=0.03), the obtained remission rate was similar among the different types of pituitary adenoma evaluated. 
We calculated also the efficacy of medical-therapy (MT) with pituitary-directed drugs (at least two consecutive 
years): overall 41% patients presented a controlled disease; MT was used more often in patients with GH and 
PRL- rather than in those with ACTH-secreting adenoma (respectively p=0.001 and p=0.029), with similar 
results on disease control considering the different adenomas. Comparing various treatments, disease control 
was better achieved with surgery than with MT in patients with ACTH-, as opposed to those with GH- and 
PRL-secreting adenoma (because in the latter MT was more effective, respectively p=0.008 and p=0.03). 
Disease control was similar between MT and radiotherapy. 
 
 
 
Table 12: description of treatment in aggressive PitNET; data are reported as percentage or mean and standard deviation 
(when specified). TNS: Trans-Nasal Surgery, MT: Medical Therapy; na: not available. NFPA were not considered 
computing total data for MT. 
 
 TNS  
(%) 
TNS  per 
patient 
TNS 
Remission (%) 
RT 
(%) 
RT Remission 
(%) 
MT 
(%) 
MT Control 
(%) 
ACTH (n=14) 14/14 
(100) 
1.6±1.1 6/14  
(43) 
5/14  
(36) 
1/5  
(20) 
6/14 
(43) 
2/6  
(33) 
GH (n=18) 18/18 
(100) 
1.3±0.7 2/18  
(11) 
2/18  
(11) 
1/2  
(50) 
17/18 
(94) 
8/17  
(47) 
PRL (n=23) 20/23 
(87) 
1±0 2/20  
(10) 
3/23  
(13) 
2/3  
(67) 
18/23 
(78) 
7/18  
(39) 
Non functioning 
(n=47) 
44/47 
(94) 
1.5±0.6 13/44  
(30) 
12/47 
(26) 
6/12  
(50) 
na na 
Total  96/102 
(94) 
1.4±0.7 23/96  
(24) 
22/102 
(22) 
10/22  
(45) 
41/55 
(75) 
17/41  
(41) 
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4.8 Temozolomide and Cabergoline in PitNET  
 
(Publication IX. Losa M, J Neurooncol 2016; New data are unpublished) 
 
In 2015 we performed a national web-based survey study of patients with aggressive pituitary adenomas or 
carcinomas treated with TMZ, on behalf of the Italian Society of Endocrinology. During the study period, 31 
patients received TMZ as a salvage therapy. Mean age at start of TMZ treatment was 58 ± 2 years, ranging 
from 39 to 78 years. The mean time from diagnosis of the pituitary adenoma and TMZ treatment was 10 ± 2 
years (range 1-35 years). 6 out of 31 patients had pituitary carcinoma (metastatic disease) at the time of TMZ 
treatment. Among the 31 patients, there were 13 cases of ACTH-secreting PitNET (42%; 11 patients had 
Cushing’s disease and the remaining two Nelson’s syndrome), 10 cases of non-functioning PitNET (32%), 5 
cases of prolactin (PRL)-secreting PitNET (16%), 2 cases of acromegaly (6%), and 1 case of thyrotropin 
(TSH)-secreting adenoma (3%). Despite previous multiple therapeutic attempts, all patients had evidence of 
progressive disease at the time of TMZ treatment. In particular, all patients had been subjected to pituitary 
surgery. Most of patients undergone more than one surgical intervention: 5 patients received one procedure, 
13 patients received two procedures, 6 patients received three procedures, 5 patients received four procedures, 
one patient received five procedures and the remaining patient received ten surgical procedures. Twenty-seven 
patients (87%) had also been treated with radiotherapy, either fractionated or radiosurgery, before TMZ 
treatment. Of these, 19 patients received one radiation treatment, 5 patients received two radiation treatments, 
and the remaining 3 patients received three radiation treatments. The median interval between the last radiation 
treatment and start of TMZ treatment was 39 months, range 0–396 months. In all cases, except three patients 
who received TMZ concomitantly with radiotherapy or one month thereafter, the tumor had recurred after the 
last radiation treatment. Moreover, all growth hormone (GH)- and TSH-secreting adenomas were resistant to 
somatostatin analogues (SSA) and all PRL-secreting adenomas were resistant to DA. 
All patients had at least one MRI three months after beginning TMZ treatment and were, therefore, included 
in the analysis of efficacy. Figure 19 summarizes the results of TMZ treatment according to the type of pituitary 
tumor. Overall, 11 patients (35%) had reduction of the tumor, while 6 patients (19%) had progressive disease 
during TMZ treatment. The remaining 14 patients (45%) had stable disease. Reduction of tumor size occurred 
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within 3 months from start of TMZ therapy in all cases. Combining patients with tumor reduction and those 
with stable disease, 25 patients (80%) had disease control during TMZ treatment. 
 
 
Figure 16: individual responses to TMZ 
 
 
The median follow-up after start of TMZ treatment was 43 months (IQR, 24–72 months). PFS at 2 years in the 
entire cohort of patients was 47.7 % (95 % CI 29.5–65.9 %). A more specific analysis on tumor recurrence 
was done in the 25 patients who had disease control during treatment and was calculated as disease control 
duration (DCD). At the end of the follow-up period, the tumor regrowth in thirteen patients (52%). The 2-year 
DCD was 59% (95 % CI 39.1–79.1%). Further treatments in the 19 patients with treatment failure or tumor 
regrowth were very heterogeneous. At the end of the follow-up period, 13 patients (42%) had died. Cause of 
death was disease progression in all cases, except two cases. As detailed before, among the 13 deceased 
patients, 4 cases did not respond to TMZ treatment while the other 7 had recurrence of disease after an initial 
response to TMZ (3 had a partial response and the other 4 stable disease). The 2-year and 4-year Overall 
Survival rates were 84% (95 % CI 70.7–97.1%) and 60% (95 % CI 40.0–79.2 %; figure 20). 
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Figure 20: Kaplan–Meier analysis showing overall survival in 31 Italian patients that received TMZ treatment for a 
PitNET 
 
 
On the basis of our data above-reported regarding aggressive PRL-secreting PitNET (medical treatment is 
more effective than surgery), recently we treated a patient with an aggressive giant PRL-secreting PitNET with 
a primary combined treatment with CAB and TMZ. A 47-year-old man presented to Emergency Department 
for visual defect and transient global amnesia. Cerebral MRI revealed a giant polylobate mass extending in the 
middle skull base, with irregular margins and median localization, occupying the sellar region. The neoplasm 
caused the stretching of the pituitary stalk and compression of the optic chiasm up to the third ventricle. 
Hormonal evaluation confirmed a PRL-secreting PitNET with secondary hypogonadotropic hypogonadism: 
basal PRL 142500 ng/mL (normal value n.v. 4.6-21.4), testosterone 3.1 nmol/L (n.v. 9.7-38.2), TSH 1.91 with 
fT4 1.67 (n.v. 0.9-1.7), morning serum cortisol 350 nmol/L (676 nmol/L after 1μ short synacthen test). Menin 
gene was wild-type. Medical treatment with dopamine-agonist (cabergoline 1.5 mg/week) was started, after 6 
weeks PRL levels were normalized (11.4 ng/mL). Despite the recovery of visual field in 2 weeks, a pituitary 
MRI after 3 months of cabergoline treatment revealed a not-significant size reduction of the PitNET. Therefore, 
the drug was increased up to 3.5 mg/week; after 6 months of treatment the PRL levels were suppressed (1.3 
ng/mL) with recovery of testosterone secretion, while MRI revealed a stable pituitary mass. The case has been 
discussed in the Pituitary Multidisciplinary Team: a gross-total resection was not feasible, and rejected by the 
patient. Therefore, we proposed a primary neoadjuvant cytoreductive TMZ treatment. 
After obtaining patients’ written consent, first cycle of TMZ was administered at 150 mg/m2 for 5 days every 
28 days, then 200 mg/m2 for 5 days every 28 days were scheduled for 13 cycles (combined with cabergoline 
1.5 mg/week). Pituitary MRI was scheduled every 3 months. The patient did not report TMZ-related adverse 
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1events and no new-onset pituitary deficiencies were observed during and after treatment. During the 
combined treatment (TMZ and cabergoline), PRL levels remained suppressed, and a dramatic reduction in the 
size and changes in the radiological features of the PitNET were observed.  
The volume of the mass was measured before, during and after TMZ discontinuation. As reported in figure 
21a, after 6 months of cabergoline and before TMZ treatment the PitNET revealed a maximum extension of 
6cm and a small hemorrhagic area (the compression of the optic chiasm and third ventricle and the stretching 
of the pituitary stalk were similar to baseline MRI). After 3 cycles of TMZ we observed a reduction of the 
overall sizes of the pituitary adenoma with regular evolution of the methaemoglobinic components and 
enlargement of the necrotic area, leading to an overall reduced compression of the third ventricle (fig 21b). 
After 6 cycles of TMZ the shrinkage of the adenoma persists, with disappearing of the methaemoglobin, and 
increase of the necrotic area (figure 1c). In figure 1d we show that after 9 cycles of TMZ a large necrotic area 
appeared, with a little remaining of tissue’s enhancement in the carotid sinus. MRI performed during follow-
up (4 and 10 months after TMZ discontinuation) revealed a stable necrotic tissue (5.9cm3) with a minimal area 
of tissue enhancement (0.5cm3, table 13). 
 
 
Table 13: Prolactin-secreting PitNET volume before and after TMZ 
 
date MRI TMZ treatment Total Volume (cm3) Total Volume  
without necrosis (cm3) 
28/01/2016 Before TMZ 17.76 15.1 
05/08/2016 After 3 months (3 cycles) 11.44 9.18 
04/11/2016 After 6 months (6 cycles) 9.05 3.15 
10/02/2017 After 9 months (9 cycles) 6.33 0.7 
21/06/2017 After 12 months (13 cycles) 5.99 0.5 
03/11/2017 4 months after TMZ discontinuation 5.94 0.5 
03/06/2018 12 months after TMZ discontinuation 5.9 0.5 
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Figure 21: Pituitary MRI and adenoma’s volume before TMZ (panel a), and after 3, 6 and 9 cycles of TMZ (respectively 
panel b, c and d).  
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5. Discussion  
 
Considering our results, a significant proportion of patients with PitNET could benefit from a complete clinical 
and molecular characterization, in order to personalize their therapeutic plan. 
 
Everolimus in PitNET 
As far as we know, we first attempt to evaluate by a molecular approach the involvement of a TSC-related 
gene variant in the pathogenesis of the PitNET. Considering the c.4006-71C>T variant causative for TSC – 
that is reasonable given the frequency of intronic mutations in TSC (i.e. 5%)103 and its absence in the normal 
population – we could exclude the involvement of pituitary gland alterations in the pathological process of 
TSC. On the other hand, however, until functional data on this variant has not been gathered, we cannot exclude 
possible alternative genetic mechanisms causative of TSC including mosaic mutations in TSC1 regulatory 
regions – the mosaicism would easily explain the mild phenotype of our patient103 – or an additional TSC 
causative gene. Nearly 10-15% of TSC patients lack, indeed, a conclusive molecular diagnosis101,102. Although 
relevant, our data are thus not conclusive for establishing unequivocally the causal nature of the association 
between TSC and PitNET that might only be a coincidence due to the relative high prevalence of pituitary 
tumors in the general population1.  
Although everolimus has been successfully tested in non-functioning and GH secreting PitNET cellular 
models110,112,113, very few data are available on its use in PitNET patients. Everolimus has been indeed used 
for treating only two patients with pituitary carcinomas resistant to repeated resections, radiations and 
combined treatment with chemotherapic agents – i.e. TMZ and Capecitabine – with limited effects114,115. Our 
data corroborate the efficacy of everolimus in reducing cell viability in non-secreting PitNET, and support the 
need of further clinical studies for demonstrating its efficacy and safety for treating this group of tumors. 
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Prediction of response to SSA in acromegaly 
The current treatment algorithms for acromegaly are based upon a “trial-and-error” approach with additional 
treatment options provided when disease is not controlled. In many other diseases, therapeutic algorithms have 
been evolving towards personalized treatment with the medication that best matches individual disease 
characteristics, using biomarkers that identify therapeutic response91. Surgical success is affected by the size 
of the tumour and the skill of the surgeon, as well as the type of surgical procedure used. Patients with a 
microadenoma (<1 cm) may reach a 90% surgical cure rate; conversely, patients with a macroadenoma (>1 
cm) and especially those with extrasellar extension have <50% chance of surgical remission3,7,80,91. Most cases 
that are not surgically cured are treated with a SSA, and response is evaluated after a few months. 
Unfortunately, treatment failure to control GH and IGF-1 secretion with first-generation SSA (octreotide and 
lanreotide) may occur in approximately half patients84. Currently, predictive factors of response to SSA include 
the following: age, SSTR phenotype, AIP expression, Ras-Raf-MEK-ERK1/2-p27 pathway, G-protein-linked 
receptor mutations, densely granular histological pattern, T2-wighted MRI signal of the adenoma and initial 
and residual (after surgery) size of tumour as previously indicated20,91. Since none of the aforementioned tools 
is able to completely predict the response to SSA, it is crucial to define also new predictive markers. In such 
scenario, we studied genetic variants (as AIP) and paradoxical response of GH after OGTT.  
Regarding genetic variants, we participate in a large multicentric Italian study in order to collect genetic 
variants and the relationship between pollution and GH-secreting PitNET. We observed that acromegaly is 
more biochemically severe and resistant to SSA treatment in patients from highly polluted areas, especially if 
they also carry specific AHR or AIP gene variants. The AHR is a transcription factor belonging to the basic 
helix-loop-helix/Per/ARNT/Sim family and is the only one that is activated by a ligand. It is stimulated by 
several natural compounds that are present in food such as indoles and flavonoids, or by tryptophan derivatives. 
The most potent AHR ligand known so far is dioxin (TCDD) but more than 400 exogenous compounds act as 
AHR ligands, most of which are environmental endocrine disruptors, including polycyclic aromatic 
hydrocarbons27,29.  
Considering response to SSA treatment, most of the proposed biomarker are studied in the adenoma’s cells, 
therefore surgery is mandatory to predict the outcome, in a non-sense vicious circle. Therefore, it is of utmost 
importance to develop new biomarker that are not related to surgery, ideally able to predict the response. The 
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GH response after OGTT, the hallmark of acromegaly diagnosis, could be one of this. We confirmed that 
impaired expression of a functional GIPR could promote the GH-paradoxical response in a proportion of 
acromegalic patients. GIP plasma levels could be high enough to chronically trigger adenylyl cyclase/cAMP 
signaling37. In addition, the stimulatory effect of IGF-1 on GIPR promoter activity in STC-1 may suggest the 
possible presence of a self-sustaining GH/IGF-I/GIP axis in these patients. Food dependency indeed might 
characterize the first phase of the disease and prolonged exposure to high circulating GH levels might induce 
persistently elevated GIP levels that continuously trigger the adenylyl cyclase/cAMP signaling cascade in the 
GIPR overexpressing GH-secreting PitNET. 
 
Long-term effects of medical treatment in acromegaly 
We considered the long-term effects of available treatments for acromegaly (medical therapy, surgery, 
radiotherapy), especially regarding their impact on the pituitary function. Hypopituitarism severe enough to 
require replacement therapy116 can occur both before and after treatment for acromegaly as a result of the 
adenoma damaging the pituitary gland, or secondary to the effects of the different treatments on pituitary 
cells7,117. The impact of central adrenal insufficiency (CAI) in acromegaly is still not entirely clear because 
some authors reported its occurrence only in patients who had undergone TNS, with or without medical 
treatment, and others excluded irradiated patients from their analyses117–120. A higher mortality rate in irradiated 
acromegalic patients and in those who developed CAI has also been reported120. There is still a shortage of 
data on other aspects, such as the effect of long-term primary medical treatment on hypothalamic-pituitary-
adrenal (HPA) axis function. We describe a large series of consecutive, unselected patients who could access 
all available treatments, with median follow-up of 13 years. We found a high overall prevalence of CAI (22%), 
similar to that previously reported117,120. Other authors reported a lower prevalence of CAI, close to 10% of all 
patients118,121. We also studied the effect of medical therapy both as primary treatment (when TNS was 
contraindicated83) and after TNS proved unsuccessful or while awaiting the effects of RT. Two patients 
developed CAI after primary medical therapy with SSA: although there have been reports of somatostatin 
inhibiting ACTH secretion122, SSA treatment did not affect HPA axis integrity in our cohort. In the present 
study we considered octreotide or lanreotide, but not pasireotide (the latest SSA to become available for 
acromegaly), so it will be interesting in future to examine the effects of this last drug on corticotroph cells, 
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given its greater affinity for SSA receptor 5, and consequent potential effect on ACTH secretion54. To our 
knowledge, there is currently no data available on the risk of cabergoline (and other DAs), or pegvisomant 
inducing CAI in acromegaly, nor any information on their role after unsuccessful TNS87,88. Our acromegalic 
patients who underwent TNS only once did not have a higher rate of CAI than those in medical treatment, 
providing they received no RT. A repeated surgery was clearly associated with the onset of CAI, harboring a 
5-fold higher risk. As expected, pituitary RT coincided with a 4-fold higher risk of CAI. This risk effect 
increased over time, the delay probably being related to a progressive fibrotic degeneration and/or vascular 
remodeling after irradiation, which can result in of HPA axis derangement. The Kaplan-Meier curve for HPA 
axis integrity showed that RT correlated with CAI more closely than TNS or medical therapy. The onset of 
CAI in irradiated patients was unrelated to the number of TNS performed before RT, whether acromegaly was 
controlled or not. Judging from our results, we would suggest medical therapy (wherever possible) after 
unsuccessful surgery, rather than RT, with a view to preserving the HPA axis, bearing in mind that both RT 
and ACTH deficiency are strongly related with a higher mortality rate in acromegaly120. 
 
Medical treatment in Cushing’s Syndrome 
Considering patients with CS we evaluated, in an observational and prospective study (all available studies in 
literature are retrospective58–60,123), the efficacy of MET to control hypercortisolism (in term of both UFC and 
LNSC). We used LC-MS/MS to routinely measure cortisol levels since 2013, because this method is accurate 
(cross-reactivity with other steroids is reduced) and cost-effective (when large numbers of samples are 
analyzed). We reported a consistent (-67% of mUFC and -57% of mLNSC) and fast reduction of cortisol levels 
after the first month of MET treatment, that continued up to the third month, achieving mUFC normalization 
in about 70% of patients, with a median dose of 1000 mg. MET was effective also in long-term treatment, 
especially after surgical failure: 13 patients continued MET for one year and 6 up to two years (one primary 
treatment in an occult EAS), without reporting severe AEs and achieving a sustained mUFC normalization. 
We observed a response to MET higher than previously described: UFC normalization rate was 57% and 43% 
of subjects (respectively reported by Valassi et al. and also Daniel et al.), describing MET doses similar to our 
cohort 59,60. Our higher response rate to MET could be related to the design of the study: we treated patients 
with planned doses of MET based upon severity of baseline hypercortisolism, and up-titrated until UFC 
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normalization. The stratification of CS severity, based upon baseline mUFC levels, could be useful to choose 
the correct starting dose and to reduce AEs. As previously reported, we confirmed that patients with CD after 
surgical failure might present with a mild hypercortisolism108,124,125. MET was able to normalize mUFC levels 
especially in patients with mild and moderate hypercortisolism after one month of treatment. At baseline 7 CS 
patients revealed mild cortisol excess (mUFC <1.5-fold ULN, being normal in 5 cases), and most of them were 
CD patients with recurrent or persistent hypercortisolism after surgical failure (pseudo-CS was excluded in all 
patients, as reported in inclusion and exclusion criteria). They were all characterized by impaired cortisol 
rhythm: they should be treated to reduce their cortisol-related comorbidities (as recently described in patients 
with normal UFC126. In selected CS patients with severe hypercortisolism or cortisol-related critical illness, 
hormonal control must be attempted first, as soon as possible after CS diagnosis123,127. In our series 10 patients 
presented with very severe hypercortisolism at baseline (3 CD, 2 ACS and 3 EAS): they started with 1000mg 
of MET. In patients with severe hypercortisolism median observed mUFC and mLNSC reduction after 1 month 
of treatment was -86% and -80%, respectively, and 7 out of 10 presented with normal UFC at last visit (after 
median 3 monts). Therefore, in patients with severe CS a prompt treatment with MET is able to reduce 
hypercortisolism quickly before definitive therapy, i.e. surgery, if feasible. As expected, patients with EAS 
presented higher cortisol levels at baseline, as previously reported 109,125, nevertheless their prompt decrease of 
cortisol levels and their required MET dose were similar to that for CD and ACS patients. The length of MET 
treatment was lower in ACS and in EAS (median 3 months, vs 12 months in CD), because in our series MET 
treatment was used before the surgical removal of cortisol- or ACTH-secreting neoplasm, in order to reduce 
quickly the hypercortisolism (and to reduce the cortisol-related surgical risk, i.e. infection or 
thromboembolism128). The recovery of circadian cortisol rhythm (mLNSC <ULN at last visit in about 40% of 
patients) was not as satisfactory as the normalization of daily cortisol excretion (mUFC) during medical 
treatment, as previously reported68,72,73,129,130. The importance of the circadian cortisol rhythm preservation in 
driving physiological processes is critical: several metabolic alterations are common among subjects with 
increased cortisol levels in the evening131, and increased LNSC is a common marker of endogenous CS132,133. 
In our cohort, the combined end-point (control of both cortisol secretion with UFC and rhythm with LNSC) 
was achieved in half patients (30% after 3 months and 50% after 12 months of therapy). Regarding AEs, MET 
was well tolerated, and none of the patients reported severe side-effects. Mild nausea and gastrointestinal pain 
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were the most reported, two patients discontinued MET after the first month of therapy (despite mUFC 
normalization), none of them developed adrenal insufficiency. We observed an increase in androgen levels in 
10 female patients, 5 complaining hirsutism (treated with spironolactone).  
 
Long-term effects of medical treatment in Cushing’s Syndrome 
We also evaluate the effect of medical treatment on some clinical parameters of cortisol-related comorbidities. 
We prospectively studied body composition changes in patients with CS, evaluated from baseline (during 
active hypercortisolism) to remission (at least 6 consecutive months of both UFC and LNSC normal levels), 
considering the differential outcome of surgical or pharmacological treatment. Although it is well known that 
body composition is impaired in active CS (especially increased visceral fat mass)74–76,79,134, contrasting data 
are reported about body composition’s changes after long-term remission. Several imaging techniques have 
been proposed to assess body composition (DXA, magnetic resonance, computed tomography, bioelectrical 
impedance analyses); however, in routine clinical practice, DXA is an accurate and precise exam that exposes 
patients to a low dose of radiations. Moreover, it is easily available, worldwide used and allows the estimation 
in the same scan of body composition and bone mineral content (that is useful also to stratify fracture risk in 
CS). Finally, DXA evaluates visceral adipose tissue: we considered R1 box (as proposed by Snijder), which is 
as accurate as computed tomography to measure visceral fat and to predict cardiovascular risk135,136. At our 
best knowledge, this is the first prospective study that consider body composition, evaluated with DXA, in a 
group of patients with hypercortisolism achieving stable remission with different treatment plan. We collected 
23 patients, evaluated for about 3 years, whose remission was obtained with surgery (n=14) or with 
pharmacological treatment (n=9). In the whole cohort considered, remission of CS led to an improvement of 
metabolic syndrome’s features (BMI, waist circumference, dyslipidaemia and blood pressure), confirming that 
successful treatment of hypercortisolism improves cardiovascular risk137. Treatment plan of CS presented 
different body composition outcomes: we observed an improvement in cardiovascular risk factors (especially 
BMI, waist circumference, hypertension, glucose levels and metabolic syndrome) and in body composition 
(mostly fat mass, in all DXA scans) after surgery. We observed an increase in glucose levels during 
pharmacological therapy: this is an expected side effect during pasireotide treatment, despite anti-diabetic 
therapy55,68. LNSC levels of the pharmacologically treated group were higher than after surgical remission, 
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despite normal. Nevertheless, in our clinical practice we measure cortisol with LC/MS-MS and we adopt 
selected thresholds in order to enhance sensitivity, to exclude also subtle cortisol secretion. In our paper follow-
up was longer after surgery than medical treatment, and probably in the latter group the observation period 
after cortisol normalization was not sufficient to achieve a modification of body composition.  
Another interesting aspects is the coagulation in CS patients. The recently published Endocrine Society 
Guidelines about hypercortisolism treatment focused the attention on prevention of possible complications of 
CS including thrombotic events6. The thrombophilic state induced by glucocorticoids excess is indeed one of 
the main determinants of increased morbidity and mortality in CD138. The basis of this coagulopathy has not 
been fully understood; the main alteration is represented by an increase in clotting factors, especially factors 
VIII and von Willebrand (vWF), which causes an elevation in thrombin generation and consequent fibrin 
thrombus formation139. This alteration of clotting factors involves the intrinsic pathway of coagulation, 
producing a shortening in activated partial thromboplastin time (aPTT). The concomitant increase in 
endogenous anticoagulants, reported in some papers, seems unable to balance the pro-coagulative 
tendency140,141. Moreover, also the fibrinolytic system has been found to be impaired in patients with 
hypercortisolism concurring to determine the high thrombotic risk of these patients138,142. Therefore, we 
evaluated the effectiveness of long-term therapy with PAS in hemostatic alterations in patients with active CD. 
Despite reduction in UFC levels (higher than that reported in previous clinical trial67,68) none of the coagulative 
parameters explored showed any significant changes during the therapy, neither at 6 nor 12 months of therapy. 
No significant differences in coagulative profile were observed between patients with normal and elevated 
UFC at 6 and 12 months. The scarce restoration of coagulative parameters might depend on persistence of 
typical alterations of CD such as obesity and hypertension and, in our series, might reflect also on the 
worsening in glycemic metabolism induced by PAS. 
 
Medical treatment in aggressive PitNET 
Aggressive PitNET are rarely identified at an early stage in routine clinical practice, representing therapeutic 
challenges for endocrinologists and neurosurgeons. Therefore, we decided to propose a combined and 
comprehensive definition of aggressive pituitary adenoma, in order to overcame some previously definition 
(ie atypical adenomas, invasive adenomas and so on), that could explain only partially the aggressiveness of 
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an adenoma. Other than atypical nature or local invasiveness, we considered other features of adenoma that 
could describe their clinical aggressiveness. As expected, patients with aggressive non-functioning PitNET 
were older: the diagnosis might be delayed until mass-symptoms occur in the former cases, while in case of 
endocrine secretion the signs or symptoms related to hormonal hypersecretion might receive a prompt 
recognition by physicians. Two thirds of patients revealed CSI, especially PRL-secreting adenomas; 
nevertheless, it is worth remembering that aggressive forms are a small part of all PRL-secreting pituitary 
adenomas, since they are both controlled with dopamine agonists and early diagnosed8. Moreover, medical 
treatment could be proposed to patients with aggressive PRL-secreting PitNET; in ordet to achieve a better 
result143. In our cohort 25% of patients with aggressive adenoma presented an “atypical adenoma” as that 
proposed in the previous WHO definition of 2004, with an observed prevalence similar among all types. 
Overall the remission rate of atypical adenoma was 61% (confirming previously reported data45). Therefore, 
we confirm that the definition of atypical adenomas was not predictive of worse outcome, thus it should not 
be longer used in clinical practice as recently underlined in the new WHO classification of pituitary tumors52,53. 
Silent adenomas are nowadays considered as a “high risk” category for aggressiveness 44,45,53. Obviously, since 
the diagnosis of silent adenoma is based upon immunohistochemistry after surgery, this marker could not be 
considered as a predictive tool of outcome before surgery. All considered characteristics of aggressiveness 
were similar among silent adenomas and NFPA, even analyzing separately silent corticotropinomas and 
gonadotropinomas. We also considered the efficacy of 2 years of consecutive MT with pituitary-directed drugs 
in patients with secreting aggressive adenoma. Less than half of the patients presented a well-controlled disease 
with MT. It has to be noticed that MT was used more frequently in patients presenting aggressive GH and 
PRL-secreting than in those with ACTH-secreting adenoma, since target therapy with PAS has been used only 
in the latter years, substituting steroidogenesis inhibitors (which are not effective to control pituitary adenoma 
growth). 
After diagnosis of aggressive PitNET, the treatment of choice is challenge and need a multidisciplinary 
approach in the era of PTCOE144. However, after several attempts with surgery, conventional medical 
treatment and radiotherapy, nowadays TMZ must have to be considered as an option. TMZ is an oral alkylating 
chemotherapeutic agent, previously indicated for glioblastoma, and is currently recommended in the treatment 
of aggressive pituitary tumors, considered as radiologically invasive tumour or those with unusually rapid 
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tumour growth rate, or clinically relevant tumour growth despite optimal standard therapies5,99,145. We 
conducted a national web-based survey study in 2015 in patients with aggressive pituitary adenomas or 
carcinomas treated with TMZ. In most neoplastic disorders, a favorable response to chemotherapy is 
considered as a measurable reduction in tumor size; nevertheless, stabilization of disease in some cases 
improves the quality of life and decreases morbidity. All our patients had tumor progression before TMZ 
treatment: in this setting, an arrest of tumor progression corresponds to a favorable clinical, although not 
radiological, response, as also suggested in previous mini-series of TMZ treated pituitary tumors. Thus, a new 
strategic approach to tumoral disease could be to stabilize it and to revisit the idea of treating cancer as a 
chronic disease. This concept may particularly apply to very aggressive pituitary tumors, for which, with the 
possible exception of some patients with severe forms of hypercortisolism, the leading cause of death is local 
growth of the tumor. Because of the aforementioned considerations, tumor reduction and stable disease were 
grouped together and considered as disease control. Overall, 81% of our patients were classified as having 
disease control. However, when we split the data of the positive response, the frequency of tumor reduction in 
Italian patients (36%) was clearly lower than that reported in the literature. It is likely that reporting bias plays 
a role, as single cases with a positive response to an innovative therapeutic treatment may have high chances 
to be described and published: it is important therefore to publish a large series, also with “negative results”, 
in order to describe the real efficacy of TMZ in clinical practice.  A positive response to TMZ was always 
recorded within 3 months of therapy. In keeping with previous suggestions5,98,100, this evidence strongly 
suggests that an alternative therapeutic strategy should be considered if disease progression is demonstrated 
within 6 months of treatment with TMZ. We could not identify baseline clinical characteristics associated with 
a favorable response to TMZ. However, it should be stressed that the small number of patients and events 
might have obscured the existence of any association, if any exists. Regrowth of the tumor after an initial 
positive response to TMZ occurred in 52 % of our patients. Treatment of patients who have a relapse after 
TMZ treatment is still a largely unmet need. 
Starting from our observation previously described (medical treatment is highly effective in aggressive 
PitNET), we proposed a TMZ primary medical treatment, never described in a patient with aggressive 
prolactin-secreting PitNET. As reported in the Endocrine Society’s Guidelines regarding PRLomas, 
cabergoline is the first-line treatment to lower hormonal levels and to decrease tumor size8. Despite size and 
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secretion, in our case the term “insufficient response to cabergoline” may be better than “resistance to 
cabergoline”, because cabergoline treatment (up to 3.5 mg/week) was effective to reduce PRL levels. In such 
cases, indication to cytoreductive surgery should be carefully considered and balanced, because complete 
surgical removal of a giant adenoma is challenging and tumour persistence after surgery occurs frequently93. 
Recently, the Pituitary Society decided to create general criterial for developing Pituitary Tumors Centers of 
Excellence (PTCOE), indicating that the best care for pituitary patients is provided by an interdisciplinary team 
composed of dedicated endocrinologists, experienced pituitary surgeons, neuroradiologists, neuropathologists, 
neuro-oncologists and other dedicated physicians and nurses144. In our patient the transsphenoidal surgery 
could only achieve a partial resection of the whole adenoma. Hence, other treatments should be considered, 
and some authors previously suggested an early chemotherapy treatment in patients with PitNET146. Therefore, 
after a multidisciplinary team evaluation, we decided to propose a cytoreductive TMZ treatment, which 
revealed its effectiveness shortly after 3 months of therapy (3 months are sufficient to evaluate an initial 
response to treatment). TMZ has few side effects, is available in oral form, and its ability to cross the blood-
brain barrier makes it superior to other chemotherapy drugs. TMZ has been previously proposed mainly after 
surgical failure in patients with aggressive PRL-secreting PitNET as a salvage therapy147–150, however in this 
case we considered TMZ as a neoadjuvant cytoriductive treatment,  after a careful balance between potential 
side effect (TMZ is an oral alkylating) and benefit. In the present case we describe the use of 12 months 
treatment with TMZ in a patient with PRL-secreting PitNET, describing a significant and prompt reduction of 
tumor volume, without reporting severe side effects or hypopituitarism, common after pituitary surgery or 
radiotherapy. Therefore, an early initiation of TMZ could be considered when the targets of pituitary surgery 
reported in the PTCOE (to eliminate pituitary secretory syndromes, to reduce or control the tumor mass and to 
preserve the normal pituitary gland function and surrounding neural structures)144 could not be achieved in 
patients with PitNET. 
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6. Conclusions and future prospects 
 
In this complex scenario, a multidisciplinary team for the management of patients with pituitary adenoma is 
fundamental, to suggest the correct treatment plan, tailored to the patient. Recently Pituitary Tumors Centers 
of Excellence have been proposed, in order to suggest the best treatment to each patient144. The major 
conclusion of this study are as follows: 
- Everolimus is effective in primary culture of non-secreting PitNET. Since no medical treatments are 
available in non-secreting PitNET, everolimus should be considered also in patients, at least in those with 
aggressive PitNET (not completely removed or with early re-growth) and in a prospective trial. 
- Most of the factors suggested to predict responsiveness to SSA in patients with acromegaly need surgical 
intervention, in order to study the cellular biology of the adenoma. We suggest three novel “surgery-
independent” biomarker (pollution, AIP-AR variants and GH response to OGTT) that can be considered 
in the therapeutic plan. 
- In patients with acromegaly, a long term primary medical treatment (more than 10 years) is effective and 
safe, especially to reduce the incidence of hypopituitarism. 
- A prospective study about medical treatment with metyrapone has never been reported. Therefore we 
conduct an observational planned study, confirming that metyrapone is effective and safe to reduce cortisol 
levels (also in patients with severe hypercortisolism) and to improve cortisol-related comorbidities. 
- Regarding body composition after achieving remission from Cushing’s Syndrome, we observe an 
improvement in cardiovascular risk factors (BMI, waist circumference, hypertension, glucose levels and 
metabolic syndrome) and in body composition (mostly fat mass, in all DXA scans) especially after surgery. 
Further studies are needed to compare directly surgery and medical treatment with strong outcomes 
(morbidity and mortality). 
- A combined definition of aggressive PitNET is needed, considering pathological, clinical and radiological 
data. In patients with aggressive PitNET temozolomide is an effective and safe option, that must be 
considered not only as salvage treatment but also at an early stage, after the identification of an aggressive 
behaviour: prospective studies are needed to explore primary TMZ treatment. 
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